Abstract: The invention provides materials and methods for the identification of cells exhibiting a cell proliferative disorder that are amenable to treatment with a herpes simplex virus that does not express an approximately wild-type level of ICP34.5. Also provided are methods of treating cell proliferative diseases, disorders or conditions, such as cancers, rheumatoid arthritis and macular degeneration, using these HSVs. Further provided are methods for preventing such cell proliferative disorders by administering the HSVs as well as methods for ameliorating a symptom associated with a cell proliferative disorder by administering such HSVs.
\section*{\textit{\textit{\gamma}_{\text{ICP34.5}}\textit{ DEFICIENT HSV AND THE MAPK PATHWAY}}}

\textbf{Government Interest}

The U.S. Government may own rights in the invention pursuant to grant no. CA7 193307-07 from the National Institutes of Health.

\textbf{Background}

In the general field of human health and animal welfare, a variety of diseases, disorders, and conditions have largely eluded the best efforts at prevention or treatment. Chief among such maladies is the loss of cell-cycle control that frequently results in the undesirable cell proliferation characteristic of cancer in its many forms. Malignant gliomas, for example, are devastating brain tumors that afflict animals such as humans. The average life span after diagnosis is less than one year and few patients have been reported to survive five years. Furthermore, none of the conventional anti-cancer therapies has been successful in significantly prolonging the lifespan of patients with this disease. Many of the more devastating forms of cancer, such as malignant gliomas and metastasized forms of a variety of cancers, are inoperable, further reducing the likelihood of receiving effective treatment with conventional therapies.

One approach to the development of new and effective anti-cancer therapies has been directed at engineered viral therapeutics. Chief among the viruses being explored for use as oncolytic agents are genetically engineered forms of herpes simplex viruses (HSV). Because wild-type viruses are highly virulent, the viruses used in preclinical evaluations and in phase-1 clinical studies have been thoroughly attenuated. While several deletion mutants have been tested, the mutants that reached clinical trials lacked a functional \textit{\gamma}_{\text{ICP34.5}} gene encoding infected cell protein 34.5 (ICP34.5).

In principle, use of an avirulent mutant of herpes simplex viruses 1 (HSV-1) to destroy cancer cells \textit{in situ}, e.g., in inoperable human tumors, is a sound approach to treating such disease conditions. As noted above, the most promising HSV candidate is an HSV mutant lacking a functional \textit{\gamma}_{\text{ICP34.5}} gene. The product of the \textit{\gamma}_{\text{ICP34.5}} gene of HSV, ICP34.5, is a multifunctional protein that blocks a major host response to infection. In brief, after the onset of viral DNA synthesis, infected cells accumulate large amounts of complementary viral RNA transcripts. The consequence of this accumulation is the activation of double-stranded RNA-dependent protein kinase R (PKR). In infected cells, activated PKR phosphorylates the \textit{\alpha} subunit of the eukaryotic translation initiation factor 2 (elF-2\textit{\alpha}).
resulting in loss of protein synthesis. In the case of HSV-I, ICP34.5 acts as a phosphatase accessory factor to recruit protein phosphatase 1α to dephosphorylate eIF-2α. As a consequence, protein synthesis continues unimpeded. Mutants derived from Δγi34.5 viruses lack the capacity to counteract PKR-induced loss of protein synthesis and cell apoptosis. Another significant property of γi34.5 mutant HSV is that they are highly attenuated in animal model systems and phase I clinical studies have demonstrated that Δγi34.5 mutants can be administered safely at escalating doses in patients with malignancy. A major impediment to the widespread use of these mutants for cancer therapy is the observation that in animal model systems, human tumor cells differ widely with respect to their ability to support the replication of γi34.5 mutant HSV. In cancer cells that do support replication of γi34.5-deficient HSV, these viral constructs exhibit lytic cytotoxicity specific to the cancer cells, and are able to act on such cells regardless of body location and distribution. Thus, a need exists in the art for effective and safe viral-based therapies to treat cell proliferation disorders such as cancers.

Investigations of eukaryotic cell physiology have revealed a variety of signal transduction pathways involved in the coordinate regulation of complex physiological processes such as cell proliferation. For example, mitogen-activated protein kinases (MAPKs) have been implicated as elements of regulatory pathways controlling cell proliferation in all eukaryotes. The MAPK pathway is organized in modules, of which there are six different modules presently known. This pathway typically contains an "upstream" (i.e., early step in the pathway) G-protein and a core module containing three kinase enzymes: a MAPK kinase kinase (i.e., MAPKKK) that phosphorylates and thereby activates a MAPK Kinase (i.e., MAPKK), which in turn phosphorylates and activates a MAPK. In one example, the ERK (extracellular-signal-regulated) pathway, Ras is a G-protein, Raf is a MAPKKK, MEK (i.e., MAPK/ERK Kinase) is a MAPKK and ERK is a MAPK. Complicating even this one example of a MAPK signal transduction pathway regulating cell proliferation is the existence of a number of isoforms for the particular kinases. For example, there are three mammalian Raf isoforms, i.e., Raf-1, A-Raf and B-Raf; two MEK isoforms, i.e., MEK1 and MEK2; and two ERK isoforms, i.e., ERK1 and ERK2. Moreover, other kinase enzymes can be substituted for the prototypes listed above. For example, in addition to Raf kinases, MEKK-I, (i.e., MEK Kinase-1), mos or Tpl-2 can activate MEK isoforms.

Complicating the regulatory picture even further, the MAPK pathway also embraces a variety of accessory proteins such as exchange factors, modulators, scaffolding
molecules, adapter proteins, and chaperones, collectively providing capacities to localize elements of the pathway, to translocate elements, to finely control the activation/inhibition of elements of the pathway and to ensure that signal propagation is achieved in an efficient and directed manner. An illustrative exchange factor is the Ras GTP/GDP exchange factor known as Son of Sevenless (SOS), a protein that promotes the exchange of GTP for GDP on Ras, thereby activating cell membrane-bound Ras. An example of a modulator involved in the MAPK pathway is SUR-8 (i.e., Suppressor of Ras-8), which binds to Raf-1 and Ras-GTP, forming a ternary complex that enhances Raf-1 activation. Two exemplary scaffolding proteins are the mammalian Kinase Suppressor of Ras (i.e., KSR) and the yeast PBS2 protein (i.e., polymyxin B sensitivity). KSR has been shown to associate with elements of the above-described module of the MAPK pathway, i.e., Raf, MEK and ERK. Consistent with its role as a scaffolding protein for elements of the pathway, KSR has been shown to either activate or inhibit the MAPK pathway, depending on the stoichiometric ratios of KSR to the elements of the pathway (e.g., Raf, MEK, and ERK). In terms of non-binding theory, either an insufficiency or an excess of KSR relative to the pathway components or elements would be expected to lead to an unorganized or poorly organized pathway impeding the capacity of the elements to cooperatively propagate a signal, e.g., a signal modulating cell proliferation. An example of an adapter protein is the mammalian 14-3-3 protein, which modulates a variety of signaling proteins, for example by changing the subcellular location of target proteins or by altering protein associations. As a consequence, 14-3-3 plays a role in regulating cell-cycle checkpoints, cell proliferation, cell differentiation and cell apoptosis. Finally, the MAPK pathway comprehends chaperones such as Hsp90, Hsp50/Cdc37, FKBP65 and Bag-1. Loss of functional chaperone activity results in reduced kinase activity and may be due to a chaperone's stabilization of kinase tertiary structure and/or a role for the chaperone in recruiting kinase, e.g., Raf-1, activators.

The preceding discussion of MAPK pathways illustrates the classes of proteins involved in these complex pathways of regulating such physiological processes as cell proliferation and cell apoptosis. Additional elements of the pathways are known in the art, as illustrated by the disclosures in Kolch, W., J. Biochem. 351:289-305 (2000) and English et al., Exp. Cell Res. 253:255-270 (1999), both of which are incorporated herein by reference in their entireties.

Applications of HSV-I oncolytic therapy have principally utilized local injection of virus directly into the tumor. For this reason, HSV-I vectors have been clinically
tested primarily in malignant gliomas which remain confined to the CNS. In the context of
developing HSV-I as a broader anticancer agent, it would be valuable to be able to
administer HSV-I systemically (intravenously or intraperitoneally) to effectively treat
disseminated metastases in addition to the primary tumor. Metastatic disease is responsible
for the vast majority of cancer deaths, often in spite of control of the primary tumor.
Moreover, a variety of human tumor types, such as melanomas, sarcomas, and carcinomas of
the colon, ovary, liver, breast, esophagus, stomach, pancreas, and lung have been reported to
overexpress MEK activity.

Thus, a need continues to exist in the art for virus-based cancer therapeutics
and corresponding methods for use in treating a variety of target cancer cells amenable to
such virus-based treatment. Accordingly, a need also exists for identifying amenable target
cancer cells suitable for virus-based anti-cancer treatment.

Summary

The invention disclosed herein satisfies at least one of the aforementioned
needs in the art by providing therapeutic agents in the form of herpes simplex viruses that do
not elaborate wild-type levels of active ICP34.5, the γ134.5 gene product. These therapeutic
agents are useful in treating target cells exhibiting a cell proliferative disorder, such as a
cancer (including a solid-tumor cancer), rheumatoid arthritis, macular degeneration and other
diseases, disorders and conditions known in the art to be associated with abnormal, preferably
elevated, cell proliferation. Further, such HSVs are shown herein to exhibit improved
replication, and hence cytotoxicity due to lytic cell cycle completion, in target cells having an
active MAPK pathway, e.g., an active Ras/Raf/MEK/ERK pathway. Delivery of γ134.5
deficient HSV, such as R3616, selectively targets and destroys human xenograft tumors that
overexpress MEK activity as compared to tumors that express lower MEK activity. La
addition, effective delivery can be achieved by a variety of routes, including systemic
administration. The results reported herein indicate that systemic delivery of γ134.5 deficient
HSV is effective in the treatment of human tumors. The invention also provides a method for
identifying or diagnosing a cell proliferative disorder amenable to treatment with the above-
described HSVs by determining the status of a MAPK pathway in a candidate target cell
exhibiting a cell proliferative disorder. Those candidate target cells that have an active
MAPK pathway are preferred target cells for administration of the above-described HSVs. In
providing methods for advantageously using viral-based therapy for the treatment of cell
proliferation diseases, disorders or conditions, the invention provides the benefit of effective
treatment for those diseases, disorders or conditions that have proven refractory to conventional treatment, such as inoperable tumors and metastasized cancers.

One aspect of the invention is drawn to a method of treating a cell proliferation (or cell proliferative) disorder comprising administration of an effective amount of a $\gamma_{134.5}$ deficient herpes simplex virus, such as a $\gamma_{134.5}$ deficient herpes simplex virus-1, comprising at least one expressible coding region of the MAPK pathway to a subject in need. In some embodiments, the method comprises administration of a $\gamma_{134.5}$ deficient herpes simplex virus-1 that comprises a coding region for MEK. In exemplary embodiments, the MEK is selected from the group consisting of MEK1 and MEK2. In some embodiments, the $\gamma_{134.5}$ deficient herpes simplex virus-1 comprises a coding region for ERK, such as ERK1 or ERK2. In some embodiments, the $\gamma_{134.5}$ deficient herpes simplex virus-1 comprises a coding region for Raf. In exemplary embodiments, the Raf is selected from the group consisting of Raf-1, A-Raf and B-Raf. In some embodiments, $\gamma_{134.5}$ deficient herpes simplex virus-1 comprises a coding region for a protein selected from the group consisting of MEK Kinase-1, mos and Tpl-2. Embodiments of the method according to this aspect of the invention may comprise administration of a $\gamma_{134.5}$ deficient herpes simplex virus-1 that comprises a coding region for Ras. In other embodiments of the method according to the invention, the coding region for the MAPK pathway encodes a variant of a member of the pathway. In particular embodiments, the variant is selected from the group consisting of K-Ras V12, K-Ras D12, H-Ras V12, K-Ras D13, N-Ras V12, Raf S338A, Raf S339A, B-Raf V600E, Raf-CAAX, RafBXB, $\Delta N3M KK1$ S218E/S222D, $\Delta N3M KK2$ S218E/S222D, ERK2 E58Q, ERK2 D122A, ERK2 S151A, ERK2 S221A, ERK2 S151D ERK L73P and a full-length MEK-ERK fusion. Other embodiments comprise administration of an effective amount of a $\gamma_{134.5}$ deficient herpes simplex virus-1 comprising at least one expressible coding region encoding a protein selected from the group consisting of a catalytically inactive mutant of PKR, a catalytically inactive mutant of eIF-2$\alpha$, a growth factor and an active mutant of a tyrosine kinase receptor, wherein the protein and encoding nucleic acid are known in the art.

In embodiments of this aspect of the invention, the $\gamma_{134.5}$ deficient herpes simplex virus-1 lacks any $\gamma_{134.5}$ gene. In some embodiments, the $\gamma_{134.5}$ deficient herpes simplex virus-1 comprises a $\gamma_{134.5}$ gene with a point mutation. Also contemplated are HSV that are $\gamma_{134.5}$ deficient due to an inability to effectively express an otherwise intact $\gamma_{134.5}$ gene. Additionally contemplated are HSV combining the various mechanisms for rendering the virus $\gamma_{134.5}$ deficient, such as by deletion of one $\gamma_{134.5}$ gene and mutation of a second
Y_{34.5} gene, for example by insertional inactivation, partial deletion, or non-silent point mutation.

The methods according to this aspect of the invention extend to methods wherein the treating ameliorates at least one symptom associated with the cell proliferation disorder. Exemplary symptoms include pain, swelling, or loss of physiological function due to cell proliferation, or a tumor mass impinging on one or more tissues or organs.

A variety of cell proliferation, or cell proliferative, disorders are comprehended by the invention, including cancer, macular degeneration, and autoimmune disease.

Another aspect of the invention is use of a Y_{34.5} deficient HSV comprising at least one expressible coding region of the MAPK pathway in the preparation of a medicament for the treatment of a patient with a cell proliferation disorder. Comprehended in various embodiments of the use are the MAPK pathway coding regions identified above in the context of describing the treatment methods according to the invention, Le., MEK (e.g., MEK1 and/or MEK2), ERK (e.g., ERK1 and/or ERK2), Raf (e.g., Raf-1, A-Raf, B-Raf), Ras, MEK Kinase-1, mos, Tpl-2, variants of each of the members of the MAPK pathway, such as K-Ras V12, K-Ras D12, H-Ras V12, K-Ras D13, N-Ras V12, Raf S338A, Raf S339A, B-Raf V600E, Raf-CAAX, Raf BXB, ΔN3MKK1 S218E/S222D, ΔN3MKK2 S218E/S222D, ERK2 E58Q, ERK2 D122A, ERK2 S151A, ERK2 S221A, ERK2 S151D ERK L73P and a full-length MEK-ERK fusion, and a catalytically inactive mutant of PKR, a catalytically inactive mutant of eIF-2α, a growth factor and an active mutant of a tyrosine kinase receptor. Additionally, the use may comprise any of a variety of Yx34.5 deficient HSV, as described herein.

Yet another aspect of the invention is a Y_{34.5} deficient HSV comprising at least one expressible coding region of the MAPK pathway. As noted for the aspects of the invention described above, the expressible MAPK pathway coding region may be a region encoding MEK (e.g., MEK1 and/or MEK2), ERK (e.g., ERK1 and/or ERK2), Raf (e.g., Raf-1, A-Raf, B-Raf), Ras, MEK Kinase-1, mos, Tpl-2, variants of each of the members of the MAPK pathway, such as K-Ras V12, K-Ras D12, H-Ras V12, K-Ras D13, N-Ras V12, Raf S338A, Raf S339A, B-Raf V600E, Raf-CAAX, Raf BXB, ΔN3MKK1 S218E/S222D, ΔN3MKK2 S218E/S222D, ERK2 E58Q, ERK2 D122A, ERK2 S151A, ERK2 S221A, ERK2 S151D ERK L73P and a full-length MEK-ERK fusion, and a catalytically inactive mutant of PKR, a catalytically inactive mutant of eIF-2α, a growth factor and an active mutant of a tyrosine
kinase receptor. This aspect of the invention comprehends a variety of HSV that are γi34.5 deficient HSV, such as a γi34.5 deficient herpes simplex virus-1 that lacks any γi34.5 gene (i.e., an HSV containing a deletion of each of the two γi34.5 genes found in wild-type HSV). Further contemplated is a γi34.5 deficient herpes simplex virus-1 that comprises a γi34.5 gene with a point mutation. Also contemplated are HSV that are γi34.5 deficient due to an inability to effectively express an otherwise intact γi34.5 gene. Additionally contemplated are HSV combining the various mechanisms for rendering the virus γi34.5 deficient, such as by deletion of one γi34.5 gene and mutation of a second γi34.5 gene, for example by insertional inactivation, partial deletion, or non-silent point mutation.

A related aspect of the invention is drawn to a composition comprising the γi34.5 deficient HSV as described above in combination with a pharmaceutically acceptable adjuvant, carrier, or diluent.

Another aspect of the invention provides a method of determining the susceptibility of a cell exhibiting a proliferative disorder to γi34.5 deficient herpes simplex virus-1 cytotoxicity comprising measuring the activity of the MEK signaling pathway in the cell, wherein an active MEK signaling pathway is indicative of the susceptibility of the cell to γi34.5 deficient HSV cytotoxicity. In some embodiments, the activity of the MEK signaling pathway in the cell is measured by determining the level of a phosphorylated form of a protein selected from the group consisting of MEKI, MEK2, ERK 1, and ERK 2, and preferably selected from either MEKI or MEK2. Some embodiments of this aspect of the invention involve the above-described method wherein the phosphorylated form of the protein is measured using an antibody specifically recognizing the phosphorylated form of the protein. The method described above may also involve measuring the activity of MEK signaling by determining the MEK haplotype, or partial genotype, of the cell, wherein a non-deficient MEK haplotype is indicative of an active MEK signaling pathway. In certain embodiments, the non-deficient MEK haplotype is homozygous wild-type MEK. Also in some embodiments, the method may involve a cell exhibiting a proliferative disorder that is a cancer cell. Also, the method described above may involve a γi34.5 deficient HSV that is an HSV lacking the capacity to express a full-length ICP34.5 at about a wild-type level of expression.

Another aspect of the invention provides a method of identifying a patient with a cell proliferative disorder that is amenable to treatment with a γi34.5 deficient HSV comprising obtaining a cell sample from the patient; and measuring the activity of the MEK
signaling pathway in the cell, wherein an active MEK signaling pathway is indicative of a patient with a cell proliferative disorder that is amenable to treatment with a γI34.5 deficient HSV. In some embodiments, the activity being measured is the level of a phosphorylated form of a protein selected from the group consisting of MEK1, MEK2, ERK1 and ERK2, preferably MEK1 or MEK2. In some embodiments of this aspect of the invention the activity of the MEK signaling pathway is measured by determining the MEK genotype of the cell, wherein a non-deficient MEK genotype is indicative of an active MEK signaling pathway. In some embodiments, the γI34.5 deficient HSV is an HSV lacking the capacity to express a full-length ICP34.5 at about a wild-type level of expression. This aspect of the invention comprehends embodiments in which the cell proliferative disorder is a cancer, a rheumatoid arthritis or a macular degeneration, and preferably a cancer such as a solid tumor cancer or a metastasized cancer.

Yet another aspect of the invention is a use of a γI34.5 deficient HSV in the preparation of a medicament for the treatment of a patient with a cell proliferative disorder comprising combining the γI34.5 deficient HSV with a pharmaceutically acceptable adjuvant, carrier, or diluent.

Yet another aspect of the invention is a method of treating an MEK+ cell exhibiting a proliferative disorder comprising contacting the cell with a therapeutically effective amount of a γI34.5 deficient HSV. In some embodiments of this aspect of the invention, the activity being measured is the level of a phosphorylated form of a protein selected from the group consisting of MEK1, MEK2, ERK1 and ERK2, preferably MEK1 or MEK2. Some embodiments of this aspect involve practice of the above-described method wherein the activity of the MEK signaling pathway is measured by determining the MEK haplotype of the cell, wherein a non-deficient MEK haplotype is indicative of an active MEK signaling pathway. In some embodiments of the method, the γI34.5 deficient HSV is an HSV lacking the capacity to express a full-length ICP34.5 at about a wild-type level of expression. In some embodiments, the cell proliferative disorder is a cancer.

In yet another aspect, the invention provides a use of a γI34.5 deficient HSV in the preparation of a medicament for the treatment of a cell exhibiting a proliferative disorder comprising combining the γI34.5 deficient HSV with a pharmaceutically acceptable adjuvant, carrier, diluent or excipient. Pharmaceutically acceptable adjuvants, carrier, diluents, and excipients are known in the art.
Other features and advantages of the invention will be better understood by reference to the brief description of the drawing and the detailed description of the invention that follow.

**Brief Description of the Drawing**

Figure 1. HSV R3616 viral yields in a variety of cells characteristic of a variety of tumors. Cells were exposed to 1 PFU/cell of R3616 in serum free medium for 2 hours, after which medium containing virus was removed and fresh medium containing 1% calf serum was added. At 36 hours post-infection, R3616 viral recovery was determined by standard plaque assay.

Figure 2. Differential protein synthesis and activation of protein kinase R (PKR) in R3616 infected cancer cell lines inversely correlates with constitutive MEK activation in uninfected cancer cell lines A. Cell lines were infected with 10 PFU/cell of HSV R3616. At 11 hours post-infection, the cells were rinsed, starved of methionine for one hour, and then incubated in methionine-free medium supplemented with 100 µCi of [35S] methionine per ml for two additional hours. At 14 hours post-infection, 20 µg of equilibrated protein lysates were electrophoretically separated in denaturing polyacrylamide gels, transferred to a PVDF membrane, and exposed to autoradiography film. B Cells were infected with 10 PFU/cell of R3616 and whole-cell lysates, harvested at 12 hours post-infection, were resolved by SDS-PAGE and immunoblotted with an antibody that recognizes the autophosphorylated form of PKR on threonine 446. In the lower panel, after overnight serum starvation, uninfected total whole-cell lysates were resolved by SDS-PAGE and immunoblotted with an antibody against the total and phosphorylated forms of ERK on threonine 202 and tyrosine 204.

Figure 3. Deletion of mutant N-ras in human fibrosarcoma cells restricts viral replication Replicate cultures of HT1080 and MCH603 cells were infected with 1 PFU of R3616 or HSV-1(F) viruses per cell in serum free medium for 2 hours, after which medium containing virus was removed and replaced with fresh medium containing 1% calf serum. At 36 hours post-infection, viral recovery was determined by standard plaque assay.

Figure 4. Diminished [35S]-methionine metabolic labeling in virus infected human fibrosarcoma cells deleted for mutant N-ras. Replicate cultures of HT1080 and MCH603 cells were infected with 10 PFU of R3616 or HSV-1(F) viruses per cell. At 11 hours post-infection, the cells were rinsed, starved of methionine for one hour, and then
incubated in methionine-free medium supplemented with 100 µCi of [35S] methionine per ml for two additional hours. At 14 hours post-infection, 20µg of equilibrated protein lysates were electrophoretically separated in denaturing polyacrylamide gels, transferred to a PVDF membrane and exposed to autoradiography film.

Figure 5. Increased PKR and eIF-2α phosphorylation in human fibrosarcoma cells deleted for mutant N-ras during R3616 infection. Replicate cultures of HT1080 and MCH603 cells were exposed to 10 PFU of R3616 or HSV-I(F) viruses per cell. Cells were harvested at 14 hours post-infection and processed as described in Example 1. The electrophoretically separated proteins were immunoblotted with antibodies recognizing the phosphorylated form of PKR on threonine 446 and the phosphorylated form of eIF-2α on serine 51, as well as for total PKR and eIF-2α.

Figure 6. Inhibition of MEK by the addition of PD98059 increases PKR autophosphorylation and suppresses the accumulation of a γ2 viral protein (gC) in HT1080 cells infected with R3616. Replicate cultures of serum-starved HT1080 cells were infected with 10 PFU of R3616 viruses per cell in the presence or absence of 40µM PD98059, as described in Example 1. Cells were harvested at 12 hours post-infection and the electrophoretically separated proteins were immunoblotted with antibodies recognizing either immediate-early [α(ICP27)], early [β(UL42)] or late [γ(gC)] viral proteins. The same lysates were immunoblotted to determine the total and phosphorylated forms of ERK1 and ERK2 (phosphorylated on threonine 202/tyrosine 204) and PKR (phosphorylated on threonine 446).

Figure 7. Differences in cytopathic effects in virus infected caMEK (constitutively active MEK) and dnMEK (dominant negative MEK) stable cell lines. Replicate cultures of HT-caMEK and HT-dnMEK cells were infected with 10 PFU of Mock, R3616 or HSV-I(F) viruses per cell. Photos were taken at 12 hours post-infection.

Figure 8. The effect of dnMEK and caMEK over-expression on R3616 viral recovery and PKR function during R3616 infection. A. Replicate cultures of HT-dnMEK, HT1080, and HT-caMEK cells were exposed to one PFU of R3616 virus per cell in serum-free medium for 2 hours, after which medium containing virus was removed and fresh medium containing 1% calf serum was added. At 36 hours post-infection, R3616 viral recovery was determined by standard plaque assay. B. To determine the influence of mutant MEK expression on PKR activation, replicate cultures of HT-dnMEK, HT1080 and HT-caMEK cells were exposed to 10 PFU of R3616 virus per cell. Cells were harvested at 12
hours post-infection and processed as described in Example 1. Electrophoretically separated proteins were immunoblotted with antibodies recognizing the total and phosphorylated form of the following proteins: ERK1 and ERK2 (phosphorylated on threonine 202 and tyrosine 204), PKR (phosphorylated on threonine 446), and eIF-2α (phosphorylated on serine 51). The same lysates were immunoblotted with antibodies recognizing immediate-early [α (ICP27)] and late [γ (gC)] viral proteins. C. R3616 viral recovery from replicate cultures of Mia-dnMEK, MiaPaCa2 and Mia-caMEK at 36 hours post-infection. D. Immunoblotting was performed on replicate lysates of the Mia-dhMEK, MiaPaCa2 and MiacaMEK cells described in Section B, above.

Figure 9. Diminished [35S]-methionine metabolic labeling in R3616 infected human fibrosarcoma cells expressing dnMEK. Replicate cultures of HT-caMEK and HT-dnMEK cells were infected with 10 PFU of R3616 or HSV-1(F) viruses per cell. At 11 hours post-infection, Mock and virus infected cells were rinsed, starved of methionine for one hour, and then incubated in methionine-free medium supplemented with 100 μCi of [35S] methionine per ml for two additional hours. At 14 hours post-infection, 20 μg of equilibrated protein lysates were electrophoretically separated in denaturing polyacrylamide gels, transferred to a PVDF membrane and exposed to autoradiography film.

Figure 10. Bioluminescence of systemically delivered R2636 in mice growing bilateral dnMEK- and caMEK-expressing tumor xenografts. HT-dnMEK and HT-caMEK tumors were established in the left and right hind limbs of athymic nude mice. Once tumors reached an average volume of 350 mm3 animals were given a single intraperitoneal injection of 9x10⁸ PFU of R2636 virus. Bioluminescence imaging was performed 5 days after intraperitoneal injection.

Figure 11. A model for the interaction between activated MEK and the suppression of PKR function during viral infection of tumor cells by Δγ134.5 mutant viruses. Activation of the extracellular signal-regulated kinase (ERK)-kinase (MEK)/ERK pathway (i.e., the MAPK pathway) by either oncogenic activating mutations of Ras isoforms, point mutations within B-Raf alleles, or receptor tyrosine kinase activation/overexpression have been shown to be involved in transformation and tumor progression. In addition, Ras-independent activation of Raf/MEK/ERK signaling is cell- and tumor type-specific. This Figure schematically illustrates that activated MEK suppresses PKR auto-phosphorylation and effectively blocks PKR-mediated eIF-2α phosphorylation. Tumor cells with activated
MEK/ERK signaling, therefore, are exquisitely permissive to AYi34.5 mutant viral replication and oncolysis.

Figure 12. In tumor regrowth studies, systemic delivery of R3616 by intraperitoneal injection resulted in oncolysis of xenografts dependent on tumor MEK activity. Tumor xenografts were established in the hindlimbs of nude mice by injection of 5x10^6 cells per animal. Tumor volume was determined by direct caliper measurement. Once tumors reached a mean volume of 115-150 mm^3, animals were treated on day 0 and day 5 with 2x10^6, 2.1x10^7, or 2x10^8 PFU intraperitoneal or 10^8 PFU intratumoral R3616. Tumor growth was measured by calculating the ratio of tumor volume V to initial tumor volume V0.

A) HT-caMEK B) HT-dnMEK C) Hep3B (high MEK activity) D) PC-3 (low MEK activity)

Figure 13. In vivo luciferase imaging of R2636 replication shows that HT-caMEK tumors permitted increasing viral replication and HT-dnMEK tumors restricted viral replication. Intraperitoneal administration of R2636 in HT-caMEK tumor bearing mice allowed viral localization to the hindlimb xenograft and subsequent replication. Tumor xenografts were established as described previously. Mice were injected with intratumoral (5x10^7 PFU) or intraperitoneal (10^8 PFU) R2636. On days 1, 3, 8, 12, and 22 following R2636 treatment, imaging of luciferase activity was performed on a charge-coupled device camera 15 minutes following IP injection of D-luciferin at 15 mg/kg body weight. A) HT-caMEK, intratumoral B) HT-dnMEK, intratumoral C) HT-caMEK, intraperitoneal D) HT-dnMEK, intraperitoneal.

Figure 14. Quantified luciferase activity from HT-caMEK and HT-dnMEK tumor-bearing mice treated with 5x10^7 PFU intratumoral or 10^8 PFU intraperitoneal R2636. Using image analysis software to process images generated from R2636-treated mice bearing HT-caMEK and HT-dnMEK xenografts, luminescence was quantified as total photon flux, calculated using an area-under-the-curve analysis (MetaMorph). The baseline luminescence in the untreated HT-caMEK tumors was 1.8x10^5 ± 5.9x10^3 photons. In HT-caMEK tumors injected intratumorally with 5x10^7 PFU of R2636, the measured photon activity was 1.8x10^6 ±6.6x10^5, 1.1x10^7 ± 3.9x10^6, 2.7x10^6 ± 1.2x10^6, 4.3x10^6 ± 3.1x10^6, and 1.6x10^7 ± 6.7x10^6 on days 1, 3, 8, 12, and 22 respectively (p = 0.042, 0.0208, 0.0726, 0.2149, and 0.0477, respectively, with reference to baseline luminescence in untreated control mice bearing HT-caMEK tumors). HT-caMEK xenografts treated with 10^8 PFU of intraperitoneal R2636 resulted in measured photon emission of 6.6x10^5 ± 1.1x10^5, 2.4x10^6 ± 1.1x10^6, 8.4x10^6 ±
2.7x10^6, 1.1x10^7 ± 5.0x10^6, and 4.8x10^7 ± 2.1x10^7 on days 1, 3, 8, 12, and 22, respectively (p = 0.0019, 0.064, 0.0163, 0.0557, and 0.0499, respectively, with reference to untreated control tumor-bearing mice). In untreated control mice bearing HT-dnMEK tumors, baseline luminescence was 9.9x10^4 ± 1.3x10^4 photons. HT-dnMEK xenografts injected intratumorally with 5x10^7 PFU R2636 resulted in measured photon activity of 4.0x10^6 ± 1.6x10^6, 6.8x10^5 ± 2.3x10^5, 6.9x10^5 ± 5.0x10^5, 9.4x10^5 ± 7.9x10^5, and 3.2x10^6 ± 2.8x10^6 on days 1, 3, 8, 12, and 22, respectively. HT-dnMEK xenografts treated with 10^8 PFU intraperitoneal R2636 resulted in measured photon activity of 5.0x10^5 ± 1.4x10^5, 2.6x10^5 ± 7.3x10^4, 2.0x10^5 ± 1.5x10^5, 4.2x10^4 ± 4.1x10^3, and 4.4x10^4 ± 1.9x10^3 on days 1, 3, 8, 12, and 22, respectively.

Figure 15. Immunohistochemistry of HT-caMEK tumor for HSV-I antigen 5 days following R3616 treatment demonstrated a different pattern of viral spread with intratumoral versus intraperitoneal injection. HT-caMEK xenografts were harvested 5 days following intratumoral (5x10^7 PFU) or intraperitoneal (10^8 PFU) injection of R3616. Tumors were formalin-fixed, paraffin-embedded, and probed with anti-HSV-1 antibody. A) Intratumoral injection (low and high power) showed viral spread outward from the needle track. B) Intraperitoneal injection showed a more diffuse pattern with multiple foci of replication.

Figure 16. Viral recovery from HT-caMEK tumors 5 days following intratumoral injection with 5x10^7 PFU R3616 or 10^8 PFU R3616 was comparable. HT-caMEK xenografts were harvested 5 days post-treatment with either intratumoral 5x10^7 PFU or intraperitoneal 10^8 PFU of R3616. Viral titers from homogenized samples were determined by standard plaque formation assays on Vero cell monolayers.

**Detailed Description**

The present invention provides materials and methods for identifying target cells exhibiting a cell proliferation disease, disorder or condition that are amenable to herpes simplex virus-based therapy. The HSV useful in methods of the invention do not express wild-type levels of ICP34.5 and, for that reason, are relatively safe, as exhibited by the attenuated virulence of such HSV. In identifying those cells that not only exhibit a cell proliferative disease, disorder or condition, but also have an active MAPK pathway, e.g., are MEK+, the methods of the invention facilitate the identification or diagnosis of those diseases, disorder or conditions amenable to treatment with such HSV. Methods of treating...
such diseases, disorders or conditions, as well as methods of ameliorating a symptom of such a disease, disorder or condition and methods of preventing such diseases, disorders or conditions, are other beneficial aspects of the invention. In combining HSVs having cytotoxic effects that are relatively specific to cells exhibiting cell proliferative disorders with target cells having an active MAPK pathway, e.g., Ras/Raf/MEK/ERK pathway, the invention provides methods for identifying or diagnosing cell diseases, disorders or conditions best suited to treatment with the modified HSV, as well as methods of preventing, treating, or ameliorating at least one symptom associated with such disease, disorder or condition.

Studies described herein demonstrate that transduction of a cell line with a constitutively active mitogen-activated protein kinase (MAPK) kinase (MEK) coding region conferred susceptibility to a γ34.5 deficient HSV, such as the HSV R3616 virus, whereas cells transduced with a dominant negative MEK coding region became more resistant to the recombinant virus (Smith et al., J. Virol. 80:1110-1120 (2006)). MEK is a key regulator in the MAPK pathway and is activated by MAPK kinase kinases (A-RAF, B-RAF, and C-RAF) which are downstream of RAS. MEK, in turn, phosphorylates its only known substrates, the MAPKs (ERK1 and ERK2). MEK is constitutively activated in a wide variety of tumors, and functions to promote cell survival (Ballif et al., Cell Growth Differ. 12:397-408 (2001), Von Gise et al., Mol. Cell. Biol. 21:2324-2336 (2001), and Xia et al., Science 270:1326-1331 (2001)) and to protect tumor cells from multiple apoptotic stimuli. Extensive analyses of the phenotype of the parent and transduced tumor cells exposed to the γ34.5 mutant virus indicated that in cells transduced with the constitutively active MEK, PKR is not activated, in contrast to cells transduced with the dominant negative MEK. Further consideration of the disclosure of the invention will be facilitated by a consideration of the following express definitions of terms used herein.

An "abnormal condition" is broadly defined to include mammalian diseases, mammalian disorders and any abnormal state of mammalian health (i.e., a mammalian condition) that is characterized by abnormal cell proliferation in an animal, such as man, relative to a healthy individual of that species. Preferably, the abnormal cell proliferation involves excess cell proliferation. Exemplary conditions include any of the wide variety of cancers afflicting humans or other animal species (e.g., mammalian species), including solid tumors and metastasized cancers, as well as rheumatoid arthritis, macular degeneration, and the like.
"Administering" is given its ordinary and accustomed meaning of delivery by any suitable means recognized in the art. Exemplary forms of administering include oral delivery, anal delivery, direct puncture or injection, including intravenous, intraperitoneal, intramuscular, subcutaneous, intratumoral, and other forms of injection, spray (e.g., nebulizing spray), gel or fluid application to an eye, ear, nose, mouth, anus or urethral opening, and cannulation.

An "effective dose" is that amount of a substance that provides a beneficial effect on the organism receiving the dose and may vary depending upon the purpose of administering the dose, the size and condition of the organism receiving the dose, and other variables recognized in the art as relevant to a determination of an effective dose. The process of determining an effective dose involves routine optimization procedures that are within the skill in the art.

An "animal" is given its conventional meaning of a non-plant, non-protist living being. A preferred animal is a mammal, such as a human.

"Ameliorating" means reducing the degree or severity of, consistent with its ordinary and accustomed meaning.

"Pharmaceutical composition" means a formulation of compounds suitable for therapeutic administration, to a living animal, such as a human patient. Typical pharmaceutical compositions comprise a therapeutic agent such as an HSV virus not elaborating a wild-type level of active ICP34.5, in combination with an adjuvant, excipient, carrier, or diluent recognized in the art as compatible with delivery or administration to an animal, e.g., a human.

"Adjuvants," "excipients," "carriers," and "diluents" are each given the meanings those terms have acquired in the art. An adjuvant is one or more substances that serve to prolong the immunogenicity of a co-administered immunogen. An excipient is an inert substance that serves as a vehicle, and/or diluent, for a therapeutic agent. A carrier is one or more substances that facilitates manipulation of a substance (e.g., a therapeutic), such as by translocation of a substance being carried. A diluent is one or more substances that reduce the concentration of, or dilute, a given substance exposed to the diluent.

"Media" and "medium" are used to refer to cell culture medium and to cell culture media throughout the application. As used herein, "media" and "medium" may be
used interchangeably with respect to number, with the singular or plural number of the nouns becoming apparent upon consideration of the context of each usage.

Mindful of the preceding definitions, it is noted that herpes simplex virus mutants lacking the γi34.5 gene, or lacking the capacity to express active ICP34.5, are not destructive to normal tissues but are potent cytolytic agents in human tumor cells in which the activation of protein kinase R (PKR) is suppressed. Thus, replication of a Δγi34.5 mutant (R3616) in 12 genetically defined cancer cell lines correlated with suppression of PKR but not with the haplotype of Ras (i.e., the Ras-specific genotype). Extensive analyses of two cell lines transduced with either dominant negative MEK (dnMEK) or constitutively active MEK (caMEK) indicated that in R3616 mutant infected cells, dnMEK enabled PKR activation and decreased virus yields, whereas caMEK suppressed PKR and enabled better viral replication and cell destruction in transduced cells in vitro or in mouse xenografts. The results indicated that activated MEK mediated the suppression of PKR and that the status of MEK predicts the ability of Δγ34.5 mutant viruses to replicate and destroy tumor cells. In addition, Δγ34.5 mutant HSV comprising one or more coding regions for the expression of heterologous gene produces) are useful in effectively converting or ensuring that a tumor cell exhibits a suppressed PKR phenotype, thereby rendering such a cell susceptible to destruction by the Δγi34.5 mutant HSV.

PKR appears to play a key role in conferring resistance to Δγi34.5 mutants. The importance of PKR to a cell's innate antiviral response to viral infection is underscored by the observation that Δγi34.5 mutants replicate to near wild-type levels in murine embryonal fibroblast (MEF) cells derived from mice lacking PKR. Moreover, Δγ34.5 HSV mutants are virulent in PKR-/- mice, but not in wild-type mice. In addition, exogenous α interferon (INF-α) effectively suppresses Δγi34.5 mutant replication in PKR+/+ MEFs, but has no effect in PKR-/- MEFs, while wild-type HSV-I was reported to be resistant to the anti-viral effects of DFN in these cells. Therefore, replication of mutants lacking γi34.5 is largely dependent on the ability of cells to activate PKR-dependent pathways of host cell defense.

PKR also exerts potent growth suppressive effects and apoptotic cell death effects induced by multiple stimuli. Alternatively, inhibition of PKR function by over-expression of catalytically inactive mutants of PKR and eIF-2α, transformed NIH 3T3 cells and primary human cells when co-expressed with large T antigen and human telomerase reverse transcriptase (hTERT) in a manner similar to the necessary mitogenic signal transmitted by activated Ras.
Growth factor withdrawal also induces PKR activation, eIF-2α phosphorylation and apoptosis in several growth factor-dependent hematopoietic cell lines. Growth factor withdrawal also downregulated the activity of MEK, a critical downstream Ras effector kinase, while overexpression of constitutively active MEK mutants protected growth factor-dependent cell lines from multiple apoptotic stimuli, including growth factor withdrawal. MEK is a key regulatory kinase activated by MAPK-kinase-kinases (A-Raf, B-Raf, C-Raf) that functions to promote cell survival. Accordingly, MEK and its only known substrate, MAPKs (ERK1 and ERK 2) are constitutively activated in a large percentage of tumors as a consequence of dysregulated growth factor secretion, tyrosine kinase receptor activation, activating mutations in Ras isoforms and somatic activating missense mutations of B-Raf.

The data disclosed herein establish that PKR activation is suppressed in a subset of cancer cells, thereby rendering them susceptible to viral replication and cytolysis by a Δγi34.5 mutant HSV, e.g., HSV R3616. Using pharmacologic inhibitors of MEK and catalytically active and inactive mutants of MEK, constitutive MEK activity was shown to suppress the viral activation of PKR. The status of MEK correlates with the ability of tumor cells to support the replication of Δγi34.5 mutant HSV viruses and that replication ultimately destroys the host tumor cells. Accordingly, the status of MEK is predictive of those cancer cells most susceptible to destruction by HSV viruses not elaborating wild-type levels of active ICP34.5.

The invention contemplates any herpes simplex virus, including HSV-I, HSV-2 and hybrids thereof, that does not express a wild-type level of ICP34.5, although it is preferred that the HSV is an HSV-I. Derivatives of these viruses are also contemplated by the invention, provided such derivatives both retain the capacity to exert a cytotoxic or cytopathic effect (i.e., lytically infect) at least one tumor cell type and do not express a wild-type level of ICP34.5. Suitable viral derivatives include HSV having at least one mutation, silent or not, in addition to any mutation associated with the failure to express a wild-type level of ICP34.5, as well as viral fragments. Preferably, such viral derivatives retain the ability to form infectious virion, eliminating the need for engineered forms of delivering the viral agent.

The invention also comprehends HSV having any known mechanism of reducing the level of expressed, active ICP34.5 below wild-type levels including, but not limited to, γi34.5 deletion mutants (i.e., Δγi34.5 mutants) that either express a truncated gene
product of reduced or undetectable activity or that do not express any gene product. Alternatively, or in conjunction with a deletion mutant, the invention contemplates an insertion mutant that reduces or eliminates the ICP34.5 activity of any expressed gene product, missense or nonsense mutations that eliminate or reduce expressed ICP34.5 activity in terms of either the level or stability of such activity, second-site mutations such as the insertion of an anti-sense coding region in the HSV genome, non-coding region mutations affecting the expression control of γi34.5 such as a down-regulating mutation in a promoter affecting γi34.5 expression, or any other HSV modification known in the art to reduce the level of expressed ICP34.5 activity below wild-type levels. Preferably, the modification of HSV, e.g., the mutation, is present in each copy of the relevant genetic element (e.g., a mutation in the coding region of γi34.5 is preferably found in both copies of γi34.5 found in the HSV genome). The invention also embraces singular modifications of HSV where the genetic element is naturally present as a single copy in HSV or where an HSV derivative has been rendered hemizygous for the relevant genetic element. Preferably, the level of expressed ICP34.5 is reduced below detectable levels.

With respect to heterologous coding regions, the invention contemplates a variety of coding regions useful in effectively suppressing PEIR when expressed. Suitable heterologous coding regions include the coding region for a functional member of the MAPK (Ras/Raf/MEK/ERK) pathway, and preferably a constitutively active member of the pathway. Exemplary Ras coding regions encode any of wild-type N-Ras (SEQ ID NO:7 encoding SEQ ID NO:8), K-Ras (SEQ ID NO:9 encoding SEQ ID NO:10) or H-Ras (SEQ ID NO:11 encoding SEQ ID NO:12), as well as mutant active Ras isoform variants. For compact yet complete disclosure, wild-type sequences of members of the MAPK pathway are provided and the sequence differences from wild type are indicated for the variants. The most common mutations are at residues C/G12, G13 and Q61. There are numerous examples of active mutant Ras isoforms known in the art including, but not limited to, K-RasV12, K-RasD12, K-RasG12, H-RasV12, K-RasD13, and N-RasV12 (Bos, 49(17):4682-9, 1989, incorporated herein by reference).

Exemplary Raf coding regions encode any one of the wild-type forms of Raf (SEQ ID NO:13 encoding SEQ ID NO:14 for B-Raf), Raf-CAAX (Leevers et al. Nature 369(6479):411-4, 1994, incorporated herein by reference), RafS338A (Diaz et al. Molecular and Cellular Biology 17(8):4509, 1997; incorporated herein by reference), RafS339A (id.), or Raf BXB (Bruder et al., Genes & Dev. 6:545-556, 1992, incorporated herein by reference.)
Further, the invention embraces V600E B-Raf (Andersen et al., Cancer Res. 164:5456-60, 2004, incorporated herein by reference notwithstanding the identification therein to V599E due to a sequence error in the publication). The variations from the wild-type Raf sequence found many of Raf-CAAX, RafS338A, RafS339A, Raf BXB, and V600E B-Raf can be present in any combination. Two isoforms of MEK are found in humans, i.e., MEK1 and MEK2. The invention comprehends wild-type MEK1 (SEQ ID NO:1, encoding SEQ ID NO:2) and wild-type MEK2 (SEQ ID NO:5 encoding SEQ ID NO:6). Also contemplated are active mutant MEKs, including constitutively active MEKs. Examples of active mutants known in the art and embraced by the invention include ΔN3MKK1 S218E/S222D, an N-terminal truncation mutant of MEK1 that also includes missense mutations at residues 218 and 222; an analogous variant (N-terminal truncation and amino acid substitutions at the equivalent of positions 218 and 222 of MEK1) of MEK2 is also contemplated (Mansour, et al., Science 265(5174):966-70, 1994, incorporated herein by reference). Further, full-length MEK1 and MEK2 proteins containing a missense mutation yielding S281E or S222D, and preferably both mutations, are contemplated.

The ERK component of the MAPK pathway is present in two isoforms, ERK1 and ERK2, in humans. Contemplated by the invention are HSV comprising coding regions for wild-type ERK, including wild-type human ERK1 (SEQ ID NOS: 15 and 17 encode SEQ ID NOS: 16 and 18, respectively, with SEQ ID NOS: 15 and 16 relating to transcript variant 1 and SEQ ID NOS: 17 and 18 relating to transcript variant 2) and/or ERK2 (SEQ ID NO: 3 encodes SEQ ID NO: 4 of ERK2) (Ernrick, et al., J. Biol. Chem. 276:46469-46479, 2001, incorporated herein by reference). Exemplary variants of ERK2 include, but are not limited to, variants known in the art such as variants containing an amino acid substitution at E58Q, D122A, S151A, or S221A (Zhang, et al., J. Biol. Chem. 278: 29901-29912, 2003, incorporated herein by reference), as well as S151D or L73P (Ernrick et al., supra).

In addition to the foregoing wild-type and variant members of the MAPK pathway, the HSV according to the invention may comprise fusion proteins, such as a MEK2-ERK1 fusion as described in Robinson, et al., Curr. Biol. 8:1141—1150, 1998, incorporated herein by reference. The MEK2-ERK1 fusion of Robinson et al. encodes a full length MEK2 (SEQ ID NO:6 encoded, e.g., by SEQ ID NO:5) fused to a coding region for a linker, such as a ten-amino acid linker (Glu-Gly), in turn fused to a full-length ERK1 (SEQ ID NO: 16 or 18 encoded, e.g., by SEQ ID NO: 15 or 17, respectively). The linker can vary in length and/or sequence, provided that it is compatible with secondary and tertiary structure formation.
required for activity as an ultimate suppressor of PKR activity. Also contemplated are full-
length fusions of MEK1-ERK1, MEK2-ERK2, MEK1-ERK2 and fusions in which the
orientation of the two proteins are reversed, along with a linker conforming to the
requirements provided above. Collectively, each of the MEK1/2-ERK1/2 and ERK1/2-
MEK1/2 fusions is referred to herein as a MEK-ERK fusion. Further, N-terminally deleted
MEK1 or MEK2, particularly N-terminal deletions of the four leucine residues contributing to the
nuclear export signal, as described in Robinson et al., supra, incorporated herein by reference, are
contemplated as elements of MEK-ERK fusions. In addition, conservative coding regions specifying
amino acids that are conservative substitutions for the above-identified wild-type variants are
envisioned (e.g., any conservative substitution for the serine residues as positions 218 and 222 in the
above-described upregulated MEK variants is contemplated). In the present context, a conservative
substitution preferably conforms to conventional understanding and more preferably conserves the
functional characteristic (contribution to activity level) of the amino acid being substituted, such as
the like susceptibility to phosphorylation of S, T, Y and other phosphorylatable amino acids (D, E, H).
Non-conservative substitutions, deletions and insertions (relative to wild-type counterparts rather than
the upregulated variants described above) that result in upregulated activity of the MAPK pathway are
also comprehended, such as those non-conservative substitutions, deletions and insertions of coding
regions of the MAPK pathway known in the art.

Beyond the various coding regions of the MAPK pathway, HSVs according to
the invention may comprise a heterologous (foreign to wild-type HSV) coding region for a
catalytically inactive mutant of PKR or for a catalytically inactive mutant of eIF-2α, as
known in the art. Further, HSV comprising a coding region for a growth factor, the
overexpression of which is known in the art to result in upregulated activity of the MAPK
pathway is suitable, as is an active mutant of a tyrosine kinase receptor that is known in the
art to regulate the activity of the MAPK pathway.

The methods of the invention comprehend any process or assay known in the
art for detecting or measuring a protein indicative of the status of a MAPK pathway in a cell.
Suitable proteins include, but are not limited to, members of the Ras/Raf/MEK/ERK module
of the MAPK pathway, e.g., any form of Ras, a G-protein specifically interacting with any
such form of Ras, Raf (A-Raf, B-Raf, Raf-1; also referred to as Raf-A, Raf-B, and Raf-C,
respectively), MEK1 (MKK1), MEK2 (MKK2), ERK1, and ERK2. Any known isoform of a
protein involved in a MAPK pathway may be the sole component detected or measured, or
may be one of a plurality of elements detected or measured, for example in the context of
assays measuring a plurality of isoforms of a given protein or assays collectively measuring
one or more isoforms of at least two proteins in a MAPK pathway. In preferred embodiments, the proteins being detected or measured are phosphorylated derivatives of the proteins, wherein the phosphorylation is known in the art to be associated with activation of that protein. Further, it is expected that accessory proteins in a MAPK pathway, e.g., exchange factors, modulators, scaffolding molecules, adapter proteins, and/or chaperones, that are known to vary in activity (whether that variance is attributable to changes in specific activity or active protein level) in a manner predictive of MAPK pathway activation, may also serve alone or in combination with other suitable proteins as the basis for detecting and/or measuring MAPK pathway status. Exemplary accessory proteins include, but are not limited to, MEKK-I, mos, Tpl-2, SOS, SUR-8, KSR, PBS2, 14-3-3, Hsp90, Hsp50/Cdc37, FKBP65, Bag-1, Rsk-1, and proteins identified in Kolch, W., Nat. Rev. Cell Biol. 6:827-837 (2005), incorporated herein by reference. Preferred accessory proteins are human proteins identified above and human orthologs of non-human proteins identified above. In other processes of the invention, comparative measures of one or more MAPK pathway proteins is obtained to provide a comparative measure indicative of MAPK pathway status. Preferred proteins for use in any of these processes include MEK1, MEK2, ERK1 and ERK2.

Yet other processes according to the invention involve haplotyping a target cell, by which is meant the partial or complete characterization of at least one genetic element involved in the expression of at least one isoform of a MAPK pathway protein indicative of MAPK pathway status. The characterizations will typically provide partial or complete sequence information for at least one genetic element, which may be obtained by any method known in the art, including but not limited to chemical or enzymatic sequencing techniques, whether automated or not. Also contemplated are hybridization-based technologies using one or more probes of any suitable length and under any suitable hybridization conditions that are compatible with the reliable identification of a particular genetic element predictive, alone or in combination with additional information, of MAPK pathway status. Preferably, the probe is an oligonucleotide of 8-50 nucleotides and stringent hybridization conditions are employed to facilitate the inferential determination of at least a partial sequence diagnostic of MAPK pathway status. Also included in the haplotyping processes of the invention are genetic complementation studies in which distinct naturally existing, or engineered, phenotype are associated with the relevant haplotypes. Any other process known in the art for determining
the absolute or relative level of activity of at least one isoform of a protein in a MAPK pathway that is predictive of MAPK pathway status is also embraced by the invention.

The invention also provides methods of treating diseases, disorders or conditions characterized by abnormal cell proliferation, typically hyperproliferation, provided

5 that the abnormally proliferating cells have a MAPK pathway of active status. Diseases, disorders or conditions suitable for treatment include any form of cancer, including solid-tumor cancers such as inoperably located tumors or metastasized cancers, as well as rheumatoid arthritis, macular degeneration, and any disease, disorder or condition characterized by abnormal cell proliferation, as would be understood in the art, provided the cells have an active MAPK pathway. A related aspect of the invention provides methods for ameliorating at least one symptom associated with such disease, disorder or condition. For example, the invention contemplates administering an effective dose of an HSV that does not express a wild-type level of active ICP34.5 to an organism suffering from a cancerous condition due to MAPK-active cancer cells, wherein the dose is sufficient to reduce the pain, swelling, or other physiological symptom attending tumor growth. A benefit provided by these methods of the invention is that the HSV therapeutic is effective in embodiments of the disease, disorder or condition that have proven refractory to treatment with conventional therapies, such as inoperable tumors of the brain or other inaccessible regions of a body as well as metastasized cancers.

10 The invention further contemplates prophylactic methods wherein a dose of an HSV, as described above, that is known to be effective in ameliorating a symptom or treating a disease, disorder or condition characterized by abnormal cell proliferation is administered to an organism at risk of developing such a disease, disorder or condition.

20 Administration of the above-described HSV compositions according to the invention is by any known route, provided that the target cell or tissue is accessible via that route. Notably, the experimental results disclosed herein establish that two isogenic tumor cell lines differing in susceptibility to the Δγ134.5 mutant R3616 were used to study the distribution and persistence of virus delivered by different routes. As expected, the virus replicated better and persisted longer in the susceptible (high MEK activity) tumors in mouse xenografts. A significant finding was that systemic administration to the tumor-bearing mouse was as effective as intratumoral delivery with regard to tumor oncolysis. Accordingly, the pharmaceutical compositions may be introduced into the subject by any conventional method, e.g., by intravenous, intradermal, intramuscular, intramammary, intraperitoneal,
intrathecal, retrobulbar, intravesicular, intrapulmonary (e.g., term release); sublingual, nasal, anal, vaginal, or transdermal delivery, or by surgical implantation at a particular site. The treatment may consist of a single dose or a plurality of doses over a period of time.

Upon formulation, solutions are administered in a manner compatible with the dosage formulation and in such amount as is therapeutically effective. Appropriate dosages may be ascertained through the use of established routine assays. As studies are conducted, further information will emerge regarding optimal dosage levels and duration of treatment for specific diseases, disorders, and conditions.

In preferred embodiments, the unit dose may be calculated in terms of the dose of viral particles being administered. Viral doses are defined as a particular number of virus particles or plaque forming units (pfu). Particular unit doses include \(10^3\), \(10^4\), \(10^5\), \(10^6\), \(10^7\), \(10^8\), \(10^9\), \(10^{10}\), \(10^{11}\), \(10^{12}\), \(10^{13}\) or \(10^{14}\) pfu. Particle doses may be somewhat higher (10- to 100-fold) due to the presence of infection-defective particles, which is determinable by routine assays known in the art.

The pharmaceutical compositions and methods of the invention are useful in the fields of human medicine and veterinary medicine. Thus, the subject to be treated (whether to treat or prevent a disease, disorder or condition, or to ameliorate a symptom thereof) may be a vertebrate, e.g., a mammal, preferably human. For veterinary purposes, subjects include, for example, farm animals such as cows, sheep, pigs, horses and goats, companion animals such as dogs and cats, exotic and/or zoo animals, laboratory animals including mice, rats, rabbits, guinea pigs and hamsters; and poultry such as chickens, turkey, ducks and geese.

Having provided a general description of the various aspects of the invention, the following disclosure provides examples illustrative of the invention, wherein Example 1 describes the materials and methods used in conducting the studies reported herein, Example 2 discloses data establishing the correlation of \(\gamma\)134.5 deficient HSV replication and the MAPK (e.g., MEK) phenotype of host cells, Example 3 reveals that an N-Ras mutation enables efficient replication of R3616 mutant HSV virus in human fibrosarcoma cells; Example 4 discloses that the inhibition of MEK by PD98059 (a known MEK inhibitor) resulted in increased levels of PKR phosphorylation, decreased viral protein accumulation, and diminished replication of mutant HSV virus R3616; Example 5 discloses data showing that viral activation of PKR by mutant HSV R3616 is suppressed in tumor cell lines that
overexpressed constitutively active MEK, while expression of dominant negative MEK increased PKR activation and restricted R3616 viral replication; Example 6 establishes that intratumoral inoculation of R3616 mutant HSV virus resulted in tumor regression in tumors expressing caMEK, but not in tumors expressing dnMEK; Example 7 shows that the systemic administration of a recombinant HSV virus R2636, expressing the gC-Luc construct, targeted tumor tissue overexpressing constitutively active MEK; and Example 8 reveals that various routes of administration of mutant HSV, including systemic delivery, are suitable for the treatment of MEK-overexpressing tumors.

Example 1

Materials and Methods

Molecular Constructs - Constitutively active MEK-I -encoding (caMEK) and dominant negative MEK-I-encoding (dnMEK) plasmids, designated pNC84 and pNC92, respectively, were provided by J. Charron (Quebec, Canada). Their constructions are detailed in Ref. 34, incorporated herein by reference. Briefly, coding sequences for serine residues 218 and 222 of human wild-type MEK-I were mutated either to aspartic acid residues (D218S and D222S), creating a constitutively active, phosphomimetic mutant, or to alanine residues (A218S and A222S) to create a dominant negative-functioning kinase mutant. The mutant MEK-I cDNAs contain an in-frame FLAG epitope at the N-terminus under the transcriptional control of a CMV promoter in the pCMV-Tag2b mammalian expression vector (Qiagen Inc. Valencia, CA). Orientation and cDNA insert sequence were confirmed by DNA sequencing.

Cell Culture - PC-3 and DU145 (human prostate cancer), Panc-1, BxPc3, and MiaPaCa2 (human pancreatic cancer) MCF7 and MDA-MB-231 (human breast cancer), DLD-1 and WiDr (Colorectal cancer), Hep3B (human hepatoma), Vero (Green Monkey Kidney) cell lines were originally obtained from the American Type Culture Collection (Manassas, VA). The Huh7 hepatoma cell line was originally obtained from J.R. Wands (Harvard Medical School, Boston, MA, USA). The HT1080 (human fibrosarcoma) cell line containing one wild-type and one oncogenic (Q61K) N-ras allele (1, 40) was also obtained from the American Type Culture Collection. HT1080 cells having lost the activated mutant N-ras allele were obtained from EJ, Stanbridge (Irvine, CA) and have been described previously and published as MCH603 (40). HT-caMEK and HT-dnMEK are clonal cell lines constructed from the parental cell line HT1080, a human fibrosarcoma. The methods of
transfection with genetic constructs pNC84 and pNC92, which express constitutively active and dominant negative MEK respectively, are described in Smith et al., J. Virol. 80:1110-1120 (2006) and Mansour et al., Biochem. 35:15529-15536 (1996), both incorporated herein by reference. The above cell lines were grown in DMEM (GIBCO/Invitrogen Corporation, Grand Island, NY)/10%FCS (Intergen, Purchase, NY)/1% penicillin-streptomycin at 37°C and 7% CO₂. HT-caMEK and HT-dnMEK were grown in medium supplemented with 500 µg/ml of G418 (Geneticin, Gibco BRL).

Viruses - HSV-I(F) is the prototype wild-type HSV-I strain (18). The derivation and properties of the recombinant virus R3616, which lacks both copies of the γi34.5 gene (11), and recombinant R2636 carrying the luciferase gene driven by the glycoprotein C (gC) promoter (gC-luc) in place of the γi34.5 gene, were reported in Nakamura et al. (ref. 37), and that description is incorporated herein by reference.

Construction of stable cell lines - Mutant FLAG-tagged caMEK-1- or dnMEK- containing plasmids were transfected into replicate cultures of HT1080 or MiaPaCa2 cells on 60 mm dishes using Superfect Reagent (Qiagen Inc. Valencia, CA). Briefly, 5 µg of plasmid DNA was diluted in 300 µl of serum and antibiotic free DMEM, complexed with Superfect (20 µl) reagent for 10 minutes at room temperature and added to cells at 37°C for 6 hours, after which medium was removed and replaced with DMEM containing 10% calf serum. After 24 hours of incubation, the cells were harvested, suspended in 5 ml of DMEM medium containing 10%FCS and 1 ml of this cellular suspension was grown on separate 100 mm dishes in a total volume of 10 ml of DMEM containing 10% calf serum supplemented with antibiotics (e.g., penicillin and streptomycin, each at conventional concentrations well-known in the art) and 800 µg/ml of G418 (Geneticin [Gibco BRL]). Medium containing G418 was replaced every four days until approximately 2 weeks after culture initiation, when cell colonies were visible and could be selected for clonal expansion using sterile cloning cylinders, as described in Gupta et al. (ref. 22), which is incorporated herein by reference. The level of FLAG-MEK expression was assessed by immunoblotting 20 µg of equilibrated lysates from isolated clones using a monoclonal antibody to the FLAG epitope (Sigma Co. St. Louis, MO). Clonal transfectants derived from the HT1080 parent cell line, designated HT-caMEK and HT-dnMEK, and from the MiaPaCa2 parent cell line, designated Mia-caMEK and Mia-dnMEK, with equivalent levels of FLAG-MEK expression, were chosen for further analysis.
Viral Infection - Cells were seeded onto 60 mm dishes at 1 x 10^6 cells per dish. The next day cells were generally exposed to the viruses (1 or 10 plaque forming units per cell (PFU/cell)) for 2 hours at 37°C and then removed and replaced with medium containing 1% calf serum. The infection continued at 37°C for the length of time indicated for each experiment. Cells were either labeled for de novo protein synthesis, harvested for immunoblotting, or collected for assaying viral recovery on Vero cell monolayers as previously described in Chou et al. (ref. 11), incorporated herein by reference.

[^35] Methionine Labeling - For metabolic labeling experiments, at 11 hours post-infection cells were washed once in warm medium 199V containing 1% calf serum lacking methionine (Sigma Chemical Co., St. Louis, MO) and incubated for an additional hour in 199V methionine-free medium after which cells were overlaid with medium 199V lacking methionine but supplemented with 100 µCi of [^35]S methionine (specific activity, >1000 Ci/mmol; Amersham Pharmacia Biotech) per ml and incubated for an additional two hours. The cells were then harvested at 14 hours post-infection, solubilized in lysis buffer [20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 IDM sodium pyrophosphate, 1 mM β-glycerol phosphate, 100 µM sodium orthovanadate, 1 µg leupeptin per ml and 1 mM PMSF], sonicated for 10 seconds, and insoluble material was removed by centrifugation. Total protein from the supernatant was quantified by the Bradford method (BioRad Laboratories, Hercules, CA) and 20 µg of equilibrated protein was subjected to electrophoresis in denaturing 12% (vol/vol) polyacrylamide gels, transferred to Polyvinylidene Difluoride membranes (PVDF; Millipore Corporation, Bedford, MA) and subjected to autoradiography.

Immunoblotting - Experiments to analyze the accumulation of viral proteins and phosphorylation of ERK, PKR and eIF-2α were performed on whole-cell lysates harvested on ice at either 12 or 14 hours post-infection with lysis buffer, sonicated for 10 seconds, and clarified by centrifugation. Total protein from the supernatant was quantified by the Bradford method and 20 µg of equilibrated protein was subjected to electrophoresis in 12% or 7.5% (vol/vol) denaturing polyacrylamide gels, transferred to PVDF membranes (Millipore Corporation), blocked, and reacted with primary antibody followed by appropriate secondary antibody.

Antibodies - Polyclonal antibodies to the total and phosphorylated forms of PKR (Thr446), eIF-2α (Ser51), and ERK (Thr202/Tyr204) were purchased from Cell Signaling Technology (Beverly, MA). Polyclonal antibody to ICP27 was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Monoclonal antibody to Glycoprotein C was purchased from Fitzgerald Industries International, Inc. (Concord, MA). Antibodies to UsII and UL42 were described in refs. 43 and 45, each incorporated herein by reference for the relevant description. Secondary antibodies (Cell Signaling Technology, Beverly, MA) were conjugated to horseradish peroxidase. Protein bands were visualized using SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL).

**Inhibitor studies** - For experiments employing the known MEK inhibitor, PD98059, HT1080 cells were starved over night in serum-free medium and then exposed to 40 μM of PD98059 (EMD Biosciences, San Diego, CA), or DMSO (1:1000 dilution) 6 hours prior to, and during, infection. At 12 hours post-infection, whole cell lysates were created as described above for immunoblotting.

**In vitro viral recovery** - Cells were exposed to viruses (1 plaque forming unit per cell (PFU/cell)) for 2 hours in serum-free medium at 37°C, after which the supernatant was aspirated and cells were overlaid with 2 ml of DMEM containing 1% calf serum and incubated at 37°C. At 36 hours post-infection, 2 ml of sterile skimmed milk was added to triplicate samples and plates were frozen at -80°C. Frozen cell suspensions were thawed and sonicated three times for 15 seconds each and titered on Vero cells.

**HTcaMEK, HTdnMEK xenograft regression studies** - HT-dnMEK and HT-caMEK tumor xenografts were established in the right flank of 5- to 6- week-old female, athymic nude mice (Fredrickson Cancer Research Institute, Bethesda, MD) by injection of 10^7 cells in 100 μl of warm phosphate-buffered saline. After one week, tumor xenografts grew to approximately 250 mm^3 and were randomized to 7 animals per treatment group. Mice were injected intratumorally with 5 x 10^7 PFU of R3616 using a Hamilton syringe. Tumor xenografts were measured biweekly with calipers and tumor volumes were calculated with the formula (1 x w x h)/2, which is derived from the formula for an ellipsoid (Tnormally^3)/g (24).

For the studies described in Example 8, tumor xenografts in athymic nude mice were established by hindlimb injection of 5 x 10^6 HT-caMEK, HT-dnMEK, Hep3B, or PC-3 tumor cells. At a mean volume of 115-150 mm^3, the tumors were treated on days 0 and 5 by administration of R3616 via intratumoral injection of 5 x 10^7 PFU or intraperitoneal injection of 10^6, 10^7, or 10^8 PFU of R3616 recombinant virus. Tumor xenografts were measured twice weekly with calipers. Tumor volume was calculated with the formula (1 x w
x h)/2, derived from the formula for the volume of an ellipsoid (d3/g). Tumor growth was measured at each time point by calculating the ratio of tumor volume (V) to initial tumor volume (VO).

**Bioluminescence Imaging** - HT-dnMEK and HT-caMEK tumor xenografts were established in the left and right hind limbs, respectively, of athymic nude mice by injection of 1 x 10^7 cells in 100 µl of warm phosphate-buffered saline. All animal studies were performed in accordance with The University of Chicago Animal Care and Use Committee standards. Once tumors grew to an average volume of 350 mm³, 9 x 10^8 PFU of virus R2636 in a total volume of 100 µl were injected intraperitoneally (IP) using a 30-gauge needle. At 5 days after IP injection, imaging of firefly luciferase in mice was performed on a charge-coupled device camera (Roper Scientific Photometries, Tucson, AZ). Animals were injected IP with 15 mg/kg body weight with D-luciferin (Biotium, Hayward, CA). After 5 minutes, animals were anesthetized with IP injection of ketamine (75 mg/kg) and xylazine (5 mg/kg) for imaging, which was performed 10 minutes after the injection of D-luciferin.

Again for the studies described in Example 8, HT-dnMEK and HT-caMEK xenografts were established in the right hindlimb of athymic nude mice by injection of 5 x 10^6 cells. At initial tumor volumes of 175 ± 60 mm³ for HT-caMEK and 131 ± 22 mm³ for HT-dnMEK, mice were injected with either intratumoral (5 x 10^7 PFU) or intraperitoneal (IP) (10^8 PFU) R2636. Animals were imaged on days 1, 3, 8, 12, and 22 following viral injection. Imaging was performed on a charge-coupled device camera (Roper Scientific Photometries, Tucson, AZ). On days of imaging, animals were injected IP with D-luciferin (Biotium, Hayward, CA) at a dose of 15 mg/kg of body weight. After 5 minutes, animals were anesthetized with IP injection of ketamine (75 mg/kg) and xylazine (5 mg/kg) for imaging, which was performed 10 minutes after injection of D-luciferin.

**Quantification of bioluminescence imaging data** - The relative intensity of transmitted light from animals infected with virus R2636 are represented as pseudocolor images with intensity ranging from low (blue) to high (red). Gray-scale images were superimposed on the pseudocolor images using MetaMorph image analysis software (Fryer Company, Huntley, Illinois). Data for total photon flux were calculated using area under the curve analysis (MetaMorph).
Example 2

Correlation of γ34.5 deficient HSV replication and MEK phenotype of host cells

The replication of R3616 (Δγi34.5) mutant virus in human tumor cell lines is cell line dependent and correlates with constitutive activation of MEK. Replicate cultures of 13 cell lines derived from human tumors were exposed to R3616 (1 PFU/cell). The cells were harvested at 36 hours post-infection and viral yields were measured by plaque assays on Vero cell monolayers. As shown in Figure 1, the yields of R3616 mutant virus were variable, ranging from 1x10^4 to 3x10^7 PFU/ml. To determine whether the variability in virus yields was reflected in the accumulation of viral proteins, cultures of human tumor cell lines were exposed to R3616 (10 PFU/cell). Vero cells were included as an example of a nonmalignant cell type that supports replication of γi34.5 deficient viruses. At 11 hours post-infection, the cells were rinsed, starved of methionine for one hour, and then incubated in methionine-free medium supplemented with 100 μCi of [35S]methionine per ml for two additional hours. At 14 hours post-infection, 20 μg of equilibrated protein lysates were electrophoretically separated in denaturing polyacrylamide gels, transferred to a PVDF membrane, and exposed to autoradiography film. As shown in Figure 2, panel A, the accumulation of viral proteins was reduced in cell lines that restricted viral replication compared to cell lines where viral yields were abundant.

To correlate the differences in the accumulation of viral proteins with the activation of PKR, replicate cultures of cell lines shown in Figure 2, panel A, were exposed to R3616 (10 PFU/cell) for 14 hours. Lysates were harvested and 20 μg of equilibrated whole-cell lysate were electrophoretically separated in denaturing polyacrylamide gels, transferred to PVDF membranes, and reacted with antibody specific for the phosphorylated form of PKR in which Thr446 is phosphorylated. As shown in the upper panels of Figure 2, B, PKR phosphorylation was elevated in the cell lines which yielded reduced viral protein accumulation (e.g., PC-3, MCF-7) and lowest in cell lines that exhibited increased levels of viral protein accumulation (e.g., HT1080, Panc-1, Hep-3B, Vero), while total PKR levels were similar.

The presence of known activating mutations within the commonly mutated oncogenic (K-, H-, N-Ras) isoforms of Ras, however, did not directly correlate with the observed differences in viral recovery from the representative cell lines identified in Figure 1. Therefore, the constitutive activity of the downstream effectors of Ras, MEK and its
substrate, ERK, which when inhibited results in the loss of the inhibitory functions of Ras on PKR (19), were examined. To determine endogenous constitutive MEK activity, uninfected cells were plated to confluence, serum-starved for 12 hours, and then immunoblotted for the phosphorylated and total forms of the MEK substrate, p42 and p44 MAPK (ERK2 and ERK1, respectively), see Figure 2 B, lower panels. Cell lines that demonstrated increased protein synthesis and suppressed PKR activation following infection with mutant R3616 demonstrated elevated baseline levels of ERK phosphorylation. In contrast, cancer cell lines that demonstrated PKR activation, inhibited protein synthesis, and decreased viral recovery following infection with R3616 demonstrated decreased or undetectable levels of ERK phosphorylation.

Example 3

*N-Ras mutation enabled efficient replication of R3616 mutant virus in human fibrosarcoma cells*

To test the hypothesis that Ras/Raf/MEK/MAPK (ERK) signaling suppresses PKR function, replication of R3616 mutant virus in two human fibrosarcoma cell lines that differ only by the expression of an oncogenic mutant allele of N-Ras were measured. HT1080 cells contain an endogenous activating mutant allele of N-Ras, whereas the MCH603 cell line, a variant of HT1080 cells in which the mutant allele has been deleted, contains only wild-type N-Ras (40). Activated MEK is a prerequisite for the Ras-dependent aggressive tumorigenic phenotype of HT1080 cells and the two cell lines differed dramatically in the constitutive levels of MEK activation, as well as in activation levels of downstream members of the Ras signaling pathway (21). The viral yields of HSV-I (F) and R3616 (1 PFU/cell) at 36 hours post-infection are shown in Figure 3. The results led to two significant observations. First, the yield of HSV-I(F) from the MCH603 cell line was approximately 10-fold lower than that obtained from HT1080 cells (3.1 x 10^7 compared to 3.5 x 10^6), respectively. Second, the yield of R3616 mutant virus in HT1080 cells was similar to that of wild-type virus (1.8 x 10^7 versus 3.1 x 10^7), indicating that γi34.5 function was not necessary during the course of infection in this cell line. In contrast, the yield of R3616 mutant virus was approximately 10-fold lower than that of wild-type virus in MCH603 cells, with yields of 4.8 x 10^5 compared to 3.5 x 10^6, respectively. Therefore, the presence of an activating N-Ras mutation enhanced the replication of both wild-type and mutant virus and that effect was greater on the virus lacking a functional γi34.5 gene.
To determine whether virus yields correlate with overall levels of the accumulation of viral proteins, replicate cultures of HT 1080 or MCH603 cells were mock-infected or exposed to viruses R3616 or HSV-1(F) (10 PFU/cell). At 11 hours post-infection, the cells were rinsed, starved of methionine for one hour, and then supplemented with 100 µCi/ml of [35S] methionine for two additional hours. At 14 hours post-infection, 20 µg of equilibrated protein lysates were electrophoretically separated in denaturing polyacrylamide gels, transferred to PVDF membranes and subjected to autoradiography. The results shown in Figure 4 are congruent with viral yields obtained from the two cell lines. Specifically, the abundance of labeled proteins in MCH603 cells infected with wild-type virus was significantly greater than that observed in the same cells infected with R3616 mutant virus, with both of the MCH603 protein yields being lower than the amounts of proteins accumulating in HT1080 cells infected with either mutant or wild-type virus.

Lastly, the correlations of each of (1) virus yields and (2) viral protein levels accumulating in infected cells with each of (3) PKR activation and (4) phosphorylation of eIF-2α were assessed. Electrophoretically separated proteins of lysates from cells infected with R3616 and HSV-1(F) (10 PFU/cell) were harvested at 14 hours post-infection and probed with antibodies to PKR and the phosphorylated forms of PKR (P-Thr446) and eIF2α (P-Ser51). As shown in Figure 5, both PKR and eIF-2α were phosphorylated in MCH603 cells infected with R3616 mutant virus. In contrast, only trace amounts of phosphorylated PKR and eIF-2α were detected in infected HT1080 cells.

Example 4

Inhibition of MEK by PD98059 resulted in increased levels of PKR phosphorylation, decreased viral protein accumulation and diminished replication of mutant virus R3616

To determine if MEK mediates the observed mutant Ras-dependent suppression of PKR activation and resultant accumulation of viral proteins in HT 1080 cells infected with mutant virus R3616, the relative expressions of representative α (ICP27), β (UL42) and γ (glycoprotein C) viral proteins in cells treated with a specific chemical inhibitor of MEK-I (PD98059) were compared. Replicate cultures of HT1080 cells were serum-starved overnight prior to exposure to equal volumes of DMSO or PD98059 (40 µM) for 6 hours prior to infection with R3616 mutant virus (10 PFU/cell). DMSO or drug treatment was then continued until the cells were harvested at 12 hours post-infection. The cells were then lysed and the lysates were subjected to electrophoresis in denaturing polyacrylamide gels, followed by transferring to PVDF membranes and reacting with antibody to ICP27,
UL42, or gC. As shown in Figure 6, panel A, treatment with PD98059 had a slight effect on the accumulation of ICP27 and UL42 proteins but a very dramatic decrease in the amounts of gC that accumulated in HT1080 cells infected with R3616. To test whether the decrease in the accumulation of gC correlated with activation of PKR, the electrophoretically separated lysates were also probed with antibody to the auto-phosphorylated form of PKR (P-Thr446). The presence of PD98059 prior to, and during, infection with R3616 increased the amount of activated PKR in HT1080 cells (Figure 6, panel B).

These results are consistent with the earlier report that in wild-type virus-infected cells, PKR activation is concurrent with the onset of viral DNA synthesis and enhanced transcription of late genes. In R3616 mutant virus-infected cells, the phosphorylation of eIF-2α by PKR causes a significant reduction of viral proteins whose accumulation is dependent on viral DNA synthesis (14). In contrast, viral proteins whose synthesis is not dependent on the onset of viral DNA synthesis (e.g., ICP27, UL42 protein) were minimally affected by the activation of PKR.

Finally, to determine if MEK inhibition affects viral replication, DMSO or PD98059 (40 μM) was added to replicate cultures of HT1080 cells 6 hours prior to, and during, infection with R3616 (1 PFU/cell). The cells were harvested at 36 hours post-infection and viral yields were measured by plaque assays on Vero cell monolayers. In the presence of PD98059, the yield of R3616 mutant virus was approximately 15-fold lower than in the presence of DMSO (4.14 x 10⁶ compared to 1.67 x 10⁵ PFU/ml).

Viral activation of PKR by mutant R3616 is suppressed in tumor cell lines that overexpress constitutively active MEK, while expression of dominant negative MEK increased PKR activation and restricted R3616 viral replication

To study the potential relationship between MEK kinase activity and PKR activation in R3616-infected cancer cells, cell lines were created that stably express either a constitutively activated mutant of MEK (caMEK) or a dominant negative mutant of MEK (dnMEK) from two tumor cell lines that differ dramatically in the magnitude of endogenous MEK activity and the ability to support R3616 viral replication. MEK is constitutively active in the HT1080 human fibrosarcoma cell line. This cell line, as shown in Figure 1-3, is also highly permissive to R3616 viral replication and demonstrates suppressed viral activation of PKR. In contrast, the MiaPaCa2 cell line, which is derived from a patient with poorly differentiated malignant pancreatic adenocarcinoma, contains oncogenic Kras mutations in
both alleles but demonstrates nearly undetectable levels of constitutively active MEK (50). The MiaPaCa2 cell line severely restricts R3616 viral replication and demonstrates robust PKR activation during R3616 viral infection.

Mutant cDNAs of human MEK-I containing mutations in serine codons at amino acid positions 218 and 222 that resulted in codons encoding negatively charged aspartate residues have been generated. These mutations mimic the effect of phosphorylation at positions 218 and 222, resulting in constitutive activation of MEK-I (MAPZ - kinase) function (27). In contrast, alanine substitutions at the same residues functionally block phosphorylation by upstream MAPK-kinase-kinases (MAPKKKs), resulting in down-regulation of endogenous MAPK activity (34). Plasmids, designated pNC84 and pNC92, containing the respective N-terminal FLAG-tagged [Asp218, Asp222 MEK-I] or [Ala218 and Ala222 MEK-I] cDNAs under the transcriptional control of a CMV promoter and the neomycin resistance gene, were used to select for G418 resistance, FLAG-MEK expressing clonal transfectants as described in Example 1.

As shown in Figure 7, when the mutant MEK-expressing HT1080 stable cell lines were infected with mutant R3616 (10 PFU/cell), there were appreciable differences in cytopathic effects (CPE). HT-caMEK cells exhibited CPE at 12 hours post-infection while HT-dnMEK-expressing cells did not. Both cell lines, however, exhibited CPE upon infection with HSV-1(F) (10 PFU/cell). Next, viral recoveries were compared from the stable transfectants generated from HT 1080 and MiaPaCa2 cells after exposure of the cells to 1 PFU of R3616 virus per cell. There was a greater than 200-fold increase in viral titer in R3616-infected caMEK cells compared with dnMEK cells, i.e., 1.18 x 10^6 compared to 1.46 x 10^8 PFU/ml for the HT1080 transfectants (caMEK v. dnMEK, respectively), and 1.05 x 10^5 compared to 5 x 10^7 PFU/ml for the MiaPaCa2 transfectants (caMEK v. dnMEK, respectively). See Figure 8, panels A and C.

Lastly, three series of experiments were done to determine whether the enhancement of replication of the R3616 mutant virus in caMEK cells correlated with increased accumulation of viral proteins and inhibition of PKR activation. In the first experiment, dnMEK- and caMEK-expressing cell lines and their respective parent cell lines were exposed to 10 PFU per cell of mutant virus R3616 (Figure 8). The cells were harvested 12 hours post-infection, solubilized, subjected to electrophoresis in denaturing polyacrylamide gels and reacted with antibodies to PKR, eDF-2α and the phosphorylated forms of PKR (P-Thr446) and cTF-2α(P-Ser51), respectively. Baseline differential MEK
activities in uninfected dnMEK- and caMEK-expressing cells and the parental cell lines were established by immunoblotting whole-cell lysates with antibody to ERK1/ERK2 and the phosphorylated form of ERK1/ERK2 (P-Thr202 and P-Tyr204, respectively), see Panels B-I and D-I of Figure 8. As shown (Panels B-3 and D-2 of Figure 8), levels of phosphorylated PKR and eIF-2α were higher in dnMEK-expressing lines infected with the R3616 mutant virus as compared with the parental cell line or the caMEK-expressing cell lines. Conversely, activated PKR was nearly undetectable in caMEK-expressing cells infected with the R3616 mutant virus.

In the second series of experiments, electrophoretically separated lysates of caMEK- or dnMEK-expressing cell lines that had been infected with the R3616 mutant virus and processed as described above were reacted with antibody to α(ICP27) and γ2 (glycoprotein C) proteins. As shown in Panel B-7 and Panel D-4 of Figure 8, the accumulation of ICP27 was similar in both the stably transfected mutant cell lines and the parental cell lines, suggesting that the expression of MEK-I mutants did not significantly affect the accumulation of ICP27, a protein expressed prior to the onset of viral DNA synthesis. However, consistent with the result shown in Figure 6 with chemical inhibition of MEK, the accumulation of gC was markedly decreased in dnMEK-expressing cell lines at 12 hours post-infection, compared with the parent or caMEK-expressing stable cells (Panel B-8 and Panel D-5 of Figure 8).

Lastly, caMEK- or dnMEK-over-expressing HT1080 cell lines were exposed to 10 PFU of virus HSV-I(F) or mutant R3616. At 11 hours post-infection, the cells were rinsed, starved of methionine for one hour, and then supplemented with 100 μCi/ml of [35S]methionine for two additional hours. At 14 hours post-infection, 20 μg of equilibrated protein lysates were electrophoretically separated in denaturing polyacrylamide gels, transferred to PVDF membranes, and exposed to autoradiography film. As shown in Figure 9, the accumulation of labeled proteins was similar in HT-caMEK (lane 5) and HT-dnMEK (lane 6) cells during infection with HSV-I(F). In contrast, the accumulation of labeled proteins in HT-dnMEK cells (lane 4) was diminished compared with HT-caMEK cells (lane 3) infected with the R3616 mutant virus.
Example 6

*Intratumoral inoculation of R3616 mutant virus resulted in tumor regression in tumors expressing caMEK but not in tumors expressing dnMEK*

To determine if differential replication correlated with a reduction of tumor size, we measured tumor volumes of untreated and R3616-treated HT-caMEK and HT-dnMEK tumor xenografts. HT-dnMEK and HT-caMEK tumor xenografts were grown to an average volume of 250 mm$^3$ and injected with a single dose of 5 x 10$^7$ PFU of R3616 or buffer on day 0. At 31 days after infection by the R3616 mutant virus, only 1/7 animals had a palpable HT-caMEK tumor (100 mm$^3$), in comparison to untreated HT-caMEK tumors, which averaged (4300 +/- 730 mm$^3$ (standard error of the mean (SEM))). In contrast, all (7/7) of the HT-dnMEK tumors were palpable, with an average tumor volume of (830 +/- SEM 210 mm$^3$) and untreated HT-dnMEK tumor volumes averaged (4000 +/- SEM 660 mm$^3$).

Example 7

*Systemic administration of a recombinant virus R2636 expressing the gC-Luc construct targeted tumor tissue over-expressing constitutively active MEK*

To determine whether differential MEK activity confers tumor-selective viral replication upon systemic delivery of a γi34.5-deficient virus, bilateral hindlimb tumor xenografts were grown by injecting the left and right hindlimbs of athymic nude mice with 5 x 10$^6$ cells of the HT-dnMEK and HT-caMEK cell lines, respectively. In order to image viral replication *in vivo*, mutant HSV R2636 was used, which is a γi34.5-deficient virus that expresses the firefly luciferase gene under the transcriptional control of the HSV-1 gC promoter, a representative γ promoter (37). This tissue that restricts viral replication, the accumulation of the firefly luciferase gene product expressed with the kinetics of a γ gene, such as gC, would be decreased over successive replicative cycles by PKR-mediated shutoff of protein synthesis. However, a Δγi34.5 mutant virus-infected, caMEK-xenografted, tumor cells, which support viral replication and gC expression, was expected to support R2636 replication and express gC-luciferase enzyme activity. At 5 days after IP delivery of R2636, bioluminescence localized to the right hindlimb, which corresponded to the caMEK-xenografted tumor (3,692 photons/mm$^2$/sec) while the dnMEK tumor xenograft demonstrated 95-fold less photon expression (39 photons/mm$^2$/sec). Also, there was no detectable bioluminescence outside of the caMEK-expressing tumors by 5 days post-IP injection (Figure 10).
Example 8

Comparative study of intratumoral and systemic delivery of virus

A series of experiments was designed to compare the intratumoral and systemic delivery of genetically engineered virus on tumor xenografts derived by injection of isogenic tumor cells differing with respect to ectopically-expressed MEK activity. General experimental techniques employed have been described in Example 1, above. Tumor xenografts were established by injecting $5 \times 10^6$ HT-caMEK or HT-dnMEK tumor cells into the hindlimbs of athymic nude mice. At a mean volume of $115 \pm 13 \text{ mm}^3$, the tumors were treated on days 0 and 5 by administration of R3616 via intratumoral injection of $5 \times 10^7$ PFU or intraperitoneal injection of $10^6$, $10^7$, or $10^8$ PFLJ of R3616 recombinant virus. Tumor xenografts were measured twice weekly with calipers. Tumor volume was calculated with the formula $(l \times w \times h)/2$, derived from the formula for the volume of an ellipsoid. Tumor growth was measured at each time point from day 0 to day 19 by calculating the ratio of tumor volume ($V$) to initial tumor volume ($V_0$). The results of these experiments are shown in Figure 12. In the HT-caMEK xenografts (Figure 12A), intraperitoneal treatment with $2\times10^6$, $2\times10^7$, or $2\times10^8$ PFU of R3616, resulted in a significant dose-dependent tumor response by 19 days ($V/V_0$ of 9.1±1.9, 7.3±1.6, and 1.5±0.6, respectively) compared to untreated HT-caMEK controls ($V/V_0$ of 14.5±1.7) ($p = 0.0221$, 0.0371, and 0.0007, respectively). In HT-dnMEK xenografts (Figure 12B), no significant effect on tumor growth was seen by day 15 with intraperitoneal administration of $2\times10^6$, $2\times10^7$, or $2\times10^8$ PFU of R3616 ($V/V_0$ of 11.2±1.9, 10.4±1.6, and 9.6±0.6, respectively) compared to untreated HT-dnMEK controls ($V/V_0$ of 9.1±3.1) ($p = 0.46$, 0.35, 0.14, respectively). Intratumoral administration of $10^8$ PFU of R3616 in HT-caMEK xenografts resulted in a significant anti-tumor effect with a $V/V_0$ of 3.2±1.1 by day 19 ($p = 0.0020$). Intratumoral administration of $10^8$ PFU of R3616 in HT-dnMEK xenografts did not demonstrate a significant anti-tumor effect with $V/V_0$ of 7.9±1.1 by day 15 ($p = 0.36$). Thus, tumor xenografts genetically engineered to express constitutively active MEK were susceptible to oncolysis following systemic delivery by intraperitoneal injection of R3616, while xenografts engineered to express dominant-negative MEK activity were resistant to R3616 oncolysis.

In the second set of experiments, xenografts were established in the hindlimbs of athymic nude mice consisting of Hep3B cells, a human hepatoma cell line, and PC-3 cells, a human prostate cancer cell line. As reported earlier, Hep3B expressed high MEK activity whereas the PC-3 cells expressed almost no MEK activity (Smith et al., J Virol 80:1110-1120...
Hep3B and PC-3 xenografts were established in nude mice by hindlimb injection of 5x10^6 cells per animal. Hep3B and PC-3 xenografts were grown to an average volume of 150±4 mm^3, and then treated on days 0 and 5 with either intratumoral injection of 5x10^7 PFU of R3616 or intraperitoneal injection of 10^6, 10^7, or 10^8 PFU of R3616. Hep3B xenografts (Figure 12C) demonstrated a dose-dependent effect with intraperitoneal administration of 2x10^6, 2x10^7, and 2x10^8 PFU of R3616 which resulted in V/V_0 of 4.3±1.0, 3.2±0.5, and 1.4±0.3 at 18 days compared to untreated Hep3B controls which reached a mean V/V_0 of 6.1+1 (p = 0.2050, 0.0858, and 0.0135, respectively).

In PC-3 xenografts (Figure 12D) there was no significant difference between intraperitoneal doses of 2x10^6, 2x10^7, and 2x10^8 PFU of R3616 (p = 0.2327, 0.0882, 0.2970, respectively) and untreated control PC-3 xenografts by day 17. Intratumoral administration of 10^8 PFU of R3616 into Hep3B xenografts (Figure 12C) resulted in a V/V_0 of 1.1+0.2 (p = 0.0130) by day 18. In PC-3 xenografts, intratumoral administration of 10^8 PFU of R3616 did not result in a significant antitumor effect with a V/V_0 of 8.9±2.2 (p = 0.102) (Figure 12D). These results demonstrated that tumor regrowth studies with natively high (Hep3B) and low (PC-3) MEK activity tumors were similar to the results obtained with tumors genetically engineered to express constitutively active or dominant-negative MEK activity.

Luciferase imaging demonstrated increased viral replication which localized to HT-caMEK tumors compared to attenuated viral replication in HT-dnMEK tumors. R2636 is a γt34.5-deficient virus constructed from the R3616 backbone that expresses the firefly luciferase gene under the control of the late HSV-1 gC promoter. Using R2636, *in vivo* imaging of viral replication was obtained. Detectable luciferase expression in tissues connotes active viral replication because gC-driven expression marks the expression of late viral structural genes. Hindlimb xenografts were established in nude mice by the injection of 5x10^6 cells of the fibrosarcoma cell lines HT-caMEK or HT-dnMEK. At initial tumor volumes of 175±60 mm^3 for HT-caMEK and 131±22 mm^3 for HT-dnMEK, mice were injected with either intratumoral (5x10^7 PFU) or intraperitoneal (10^8 PFU) R2636. Animals were imaged on days 1, 3, 8, 12, and 22 following viral injection.

In HT-caMEK xenografts that received intratumoral injections (Figure 13A), an increase in luminescence remained localized to the hindlimb only. In HT-dnMEK xenografts injected intratumorally, luminescence reached a plateau early in the study and demonstrated much lower activity than their HT-caMEK counterparts injected intratumorally (Figure 13B). HT-caMEK tumor-bearing mice (Figure 13C) that received intraperitoneal
R2636 demonstrated an increase in luminescence in the abdominal cavity (in the liver or spleen) on day 1 that disappeared by day 3 and remained absent up to the conclusion of the study at day 22, while a steady increase in luminescence was observed in the hindlimb bearing xenografted tumors. HT-dnMEK tumor-bearing mice treated by intraperitoneal injection demonstrated a similar increase in luminescence in the abdominal cavity, liver and spleen, on day 1 and day 3, which abated by day 8 and remained absent up to the conclusion of the study on day 22, with no localization to the hindlimb xenografts. Luminescence was measured and relative intensity quantified as total photon flux (Figure 14). HT-dnMEK tumors treated with either intratumoral or intraperitoneal R2636 failed to demonstrate significantly increased luminescence above the baseline luminescence measured in untreated HT-dnMEK control tumors.

To study intratumoral distribution of R3616 in HT-caMEK tumors following IT or IP injection, xenografts were harvested 5 days after treatment with either 5x10^7 PFU of intratumoral or 10^8 PFU of intraperitoneal R3616. Immunohistochemistry (IHC) for HSV-I antigen in HT-caMEK xenografts injected intratumorally demonstrated viral replication along the needle track. (Figure 15A). In contrast, HT-caMEK xenografts treated by intraperitoneal injection demonstrated a more diffuse pattern of viral distribution with multiple foci of viral replication throughout the tumors. (Figure 15B). No HSV-I antigens were detected by IHC in HT-dnMEK xenografts 5 days following intratumoral or intraperitoneal injection. To examine recovery of R3616 from HT-caMEK tumors following treatment with either intratumoral or intraperitoneal R3616, HT-caMEK xenografts were harvested 5 days post treatment with either intratumoral 5x10^7 PFU or intraperitoneal 10^8 PFU of R3616. Viral titers from homogenized samples were determined by standard plaque formation assays on Vero cell monolayers. Intratumoral administration of 5x10^7 PFU of R3616 yielded a titer of 4x10^5±1x10^5 PFU. Intraperitoneal administration of 10^8 PFU of R3616 yielded a comparable titer of 2x10^5±1x10^5 PFU (Figure 16). No detectable levels of R3616 were recovered from HT-dnMEK xenografts treated with either intraperitoneal 10^7 or 10^6 PFU at day 5.

Systemic delivery of R3616 was explored because of the observation that MEK activity suppressed PKR following tumor cell infection with R3616 and thereby increased viral recovery from tumors injected with the virus. Salient observations on the systemic administration of HSV-1 arising from the studies reported herein are: i) R3616 demonstrated greater oncolytic activity in xenografted flank tumors with high levels of active
MRK as compared with tumors that expressed lower levels of active MEK. This finding held true in human tumors genetically engineered to express constitutively active MEK, as well as tumors that natively express high MEK activity. ii) The superior oncolytic effects of R3616 in high MEK-activity tumors are corroborated by in vivo imaging studies with R2636, a Δγi34.5 mutant based on the R3616 backbone in which the late viral promoter for gC drives luciferase expression. In vivo imaging with R2636 demonstrated that systemic administration permitted Δγi34.5 mutant virus localization to constitutively active MEK tumors with subsequent intratumoral viral replication. In contrast, in dominant-negative MEK xenografts, R2636 replication was diminished and systemic administration of R2636 did not lead to persistent intratumoral viral replication, iii) Although equal amounts of virus were recovered from caMEK-expressing tumors five days following intraperitoneal administration as compared with intratumoral administration, the kinetics of viral proliferation differed, as reflected by quantified bioluminescence imaging.

Although, intraperitoneal delivery of virus required a two-fold higher dose compared to intratumoral injection to achieve the same oncolytic efficacy, the data reported herein establish that systemic delivery of R3616 effectively treated metastases from these tumors. Also, assays of MEK activation and other kinases in tumors is expected to allow for individualized targeted therapy with R3616 or similar viruses, i.e., γi34.5 deficient HSV, including Δγi34.5 HSV. Notably, anti-HSV-1 immune activity has not been reported to limit the use of Δγi34.5 mutants in human trials to date. The data disclosed herein indicate that Δγi34.5 mutant viruses will be useful in the treatment of disseminated metastatic disease. The following references, numbered 1-36 and 38-50, have been cited throughout this disclosure and are hereby incorporated by reference in their entirities.


domain variants of the interferon-induced enzyme RNA-dependent protein kinase, J. Biol. Chem. 270:17423-17428.


14. Chou, J., and B. Roizman. 1994. Herpes simplex virus 1 gamma(1)34.5 gene function, which blocks the host response to infection, maps in the homologous domain of the genes expressed during growth arrest and DNA damage. Proc Natl Acad Sci (USA) 91:5247-51.


Numerous modifications and variations of the invention are possible in view of the above teachings and are within the scope of the invention. The entire disclosures of all publications cited herein are hereby incorporated by reference.
Claims

What is claimed is:

1. A method of treating a cell proliferation disorder comprising administration of an effective amount of a γi34.5 deficient herpes simplex virus-1 comprising at least one expressible coding region of the MAPK pathway to a subject in need.

2. The method according to claim 1 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for MEK.

3. The method according to claim 2 wherein the MEK is selected from the group consisting of MEK1 and MEK2.

4. The method according to claim 1 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for ERK.

5. The method according to claim 4 wherein the ERK is selected from the group consisting of ERK1 and ERK2.

6. The method according to claim 1 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for Raf.

7. The method according to claim 6 wherein the Raf is selected from the group consisting of Raf-1, A-Raf and B-Raf.

8. The method according to claim 1 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for Ras.

9. The method according to claim 1 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for a protein selected from the group consisting of MEK Kinase-1, mos and Tpl-2.

10. The method according to claim 1 wherein the coding region for the MAPK pathway encodes a variant of a member of the pathway.

11. The method according to claim 10 wherein the variant is selected from the group consisting of K-Ras V12, K-Ras D12, K-Ras G12, H-Ras V12, K-Ras D13, N-Ras V12, Raf S338A, Raf S339A, B-Raf V600E, Raf-CAAX, Raf BXB, ΔN3MKK1 S218E/S222D, ΔN3MKK2 S218E/S222D, ERK2 E58Q, ERK2 D122A, ERK2 S151A, ERK2 S221A, ERK2 S151D ERK L73P and a full-length MEK-ERK fusion.
12. A method of treating a cell proliferation disorder comprising administration of an effective amount of a γi34.5 deficient herpes simplex virus-1 comprising at least one expressible coding region encoding a protein selected from the group consisting of a catalytically inactive mutant of PKR, a catalytically inactive mutant of eIF-2α, a growth factor and an active mutant of a tyrosine kinase receptor.

13. The method according to claim 1 wherein the γi34.5 deficient herpes simplex virus-1 lacks any γi34.5 gene.

14. The method according to claim 1 wherein the γi34.5 deficient herpes simplex virus-1 comprises a γi34.5 gene with a point mutation.

15. The method according to claim 1 wherein the treating ameliorates at least one symptom associated with the cell proliferation disorder.

16. The method according to claim 1 wherein the cell proliferation disorder is a cancer.

17. Use of a γi34.5 deficient HSV comprising at least one expressible coding region of the MAPK pathway in the preparation of a medicament for the treatment of a patient with a cell proliferation disorder.

18. A γi34.5 deficient HSV comprising at least one expressible coding region of the MAPK pathway.

19. The γi34.5 deficient HSV according to claim 18 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for MEK.

20. The γi34.5 deficient HSV according to claim 19 wherein the MEK is selected from the group consisting of MEK1 and MEK2.

21. The γi34.5 deficient HSV according to claim 18 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for ERK.

22. The γi34.5 deficient HSV according to claim 21 wherein the ERK is selected from the group consisting of ERK1 and ERK2.

23. The γi34.5 deficient HSV according to claim 18 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for Raf.

24. The γi34.5 deficient HSV according to claim 23 wherein the Raf is selected from the group consisting of Raf-1, A-Raf and B-Raf.
25. The γi34.5 deficient HSV according to claim 18 wherein the coding region encodes a protein selected from the group consisting of MEK Kinase-1, mos and TpI-2.

26. The γi34.5 deficient HSV according to claim 18 wherein the γi34.5 deficient herpes simplex virus-1 comprises a coding region for Ras.

27. The γi34.5 deficient HSV according to claim 18 wherein the coding region of the MAPK pathway encodes a variant of a member of the pathway.

28. The γi34.5 deficient HSV according to claim 27 wherein the variant is selected from the group consisting of K-Ras V12, K-Ras D12, H-Ras V12, K-Ras D13, N-Ras V12, Raf S338A, Raf S339A, B-Raf V600E, Raf-CAAX, Raf BXB, ΔN3MKK1 S218E/S222D, ΔN3MKK2 S218E/S222D, ERK2 E58Q, ERK2 D122A, ERK2 S151A, ERK2 S221A, ERK2 S151D ERK L73P and a full-length MEK-ERK fusion.

29. The γi34.5 deficient HSV according to claim 18 wherein the coding region encodes a protein selected from the group consisting of a catalytically inactive mutant of PKR, a catalytically inactive mutant of eIF-2α, a growth factor and an active mutant of a tyrosine kinase receptor.

30. The γi34.5 deficient HSV according to claim 18 wherein the γi34.5 deficient herpes simplex virus-1 lacks any γi34.5 gene.

31. The γi34.5 deficient HSV according to claim 18 wherein the γi34.5 deficient herpes simplex virus-1 comprises a γi34.5 gene with a point mutation.

32. A composition comprising the γi34.5 deficient HSV according to claim 18 in combination with a pharmaceutically acceptable adjuvant, carrier, or diluent.
**FIG. 3**

![Graph showing viral titer comparison between HT1080 and MCH603 with R3616 and HSV-1(F).](image)
FIG. 4
FIG. 5

14 HOURS AFTER INFECTION

<table>
<thead>
<tr>
<th></th>
<th>MOCK</th>
<th>R3616</th>
<th>HSV-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>HT1060</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCH603</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HT1060</td>
<td>PKR</td>
<td>PKR</td>
<td>PKR</td>
</tr>
<tr>
<td>MCH603</td>
<td>PKR</td>
<td>PKR</td>
<td>PKR</td>
</tr>
<tr>
<td>HT1060</td>
<td>eIF-2α-P-Ser51</td>
<td>eIF-2α-P-Ser51</td>
<td>eIF-2α-P-Ser51</td>
</tr>
<tr>
<td>MCH603</td>
<td>eIF-2α-P-Ser51</td>
<td>eIF-2α-P-Ser51</td>
<td>eIF-2α-P-Ser51</td>
</tr>
</tbody>
</table>

1 2 3 4 5 6
FIG. 6

HT1080 CELLS 12 HOURS AFTER INFECTION

<table>
<thead>
<tr>
<th></th>
<th>R3616</th>
<th>MOCK</th>
<th>R3616</th>
</tr>
</thead>
<tbody>
<tr>
<td>DMSO</td>
<td>DMSO</td>
<td>DMSO</td>
<td>DMSO</td>
</tr>
<tr>
<td>PD98059</td>
<td>PD98059</td>
<td>PD98059</td>
<td>PD98059</td>
</tr>
<tr>
<td>ICP27</td>
<td>ERK1&amp;2-P-Thr202/Tyr204</td>
<td></td>
<td></td>
</tr>
<tr>
<td>U42</td>
<td>PKR-P-Thr-446</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gC</td>
<td>PKR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
</tr>
</tbody>
</table>
FIG. 7

Mock  
HT-caMEK  
HT-dnMEK

R3616  
HT-caMEK  
HT-dnMEK

(10PFU/cell) at 12h p.i.  
(10PFU/cell) at 12h p.i.

HSV-1(F)  
HT-caMEK  
HT-dnMEK
FIG. 8
FIG. 10

5 days post IP injection 9 x 10^8 PFU
FIG. 12

A) Untreated Control
IT 5x10^7 pfu
IP 1x10^6 pfu
IP 1x10^7 pfu
IP 1x10^8 pfu

B) Untreated Control
IT 5x10^7 pfu
IP 1x10^6 pfu
IP 1x10^7 pfu
IP 1x10^8 pfu

C) Untreated Control
IT 5x10^7 pfu
IP 1x10^6 pfu
IP 1x10^7 pfu
IP 1x10^8 pfu

D) Untreated Control
IT 5x10^7 pfu
IP 1x10^6 pfu
IP 1x10^7 pfu
IP 1x10^8 pfu

E) Untreated 1x10^8 pfu
FIG. 13

Days | A) | B) | C) | D)
--- | --- | --- | --- | ---
1    | ![Image A1] | ![Image B1] | ![Image C1] | ![Image D1]
3    | ![Image A3] | ![Image B3] | ![Image C3] | ![Image D3]
8    | ![Image A8] | ![Image B8] | ![Image C8] | ![Image D8]
22   | ![Image A22] | ![Image B22] | ![Image C22] | ![Image D22]
FIG. 14

Bioluminescence in fibrosarcoma xenografts treated with R2636

Phots /

[Graph showing bioluminescence measurements over days]
FIG. 16

Viral Titer (pfu)

IT 5x10^7 pfu

IP 1x10^8 pfu

Treatment Group